PF-[ADDRESS_1055040] OF CARBAMAZEPI[INVESTIGATOR_769030]-07321332 BOOSTED WITH RITONAVIR IN 
HEALTHY PARTICIPANTS
Study Intervention Number : PF-07321332
Study Intervention Name: N/A
USIND Number: [ADDRESS_1055041] Number: N/A
ClinicalTrials.gov ID: N/A
Protocol Number: C4671014
Phase: 1
Brief Title: A Phase 1 Study to Estimate Effects of Carbamazepi[INVESTIGATOR_769031]-07321332/Ritonavir in Health y Participants
This document and accompanying materials contain confidential information belonging to [COMPANY_007]. Except as 
otherwise agreed to in writing, by [CONTACT_185586] s, you agree to hold this 
information in confidence and not copy or disclose it to others (except where required by [CONTACT_1289] ) or 
use it for unauthorized purposes. In the event of any actual or suspected breach of this obligation, [COMPANY_007] 
must be promptly notified.

PF-[ADDRESS_1055042] of country  health authorities and IRBs/ECs. 
Protocol Amendment Summary of Changes Table
Amendment 1 ( 02-July- 2021)
Overall Rationale for the Amendment: This study  is being amended to reflect changes in 
response to comments from FDA . Detailed changes are summarized below in a tabular form.
Section # and Name [CONTACT_769093]
[CONTACT_338228][INVESTIGATOR_769032].Per FDA request, rifampin will 
not be used as the nitrosamine 
impurities are above acceptable 
limits. Recommended CYP3A4 
inducer by [CONTACT_769083][INVESTIGATOR_050].
Section 1.1 Rationale 
and Brief SummaryUpdated rationale and information of 
carbamazepi[INVESTIGATOR_769033] 1.2 Schema Updated for carbamazepi[INVESTIGATOR_769034].
Section 1.3 Schedule 
of ActivitiesUpdated for carbamazepi[INVESTIGATOR_769035]
Added clarification that “HBsAb”
is a reflext test
Added “HLA -A*3101 and 
HLA -B*1502”
Removed “ QuantiFERON TB 
Gold Test ”New SOA required for 
carbamazepi[INVESTIGATOR_050] .
Per PCRU suggestion since 
it’s a reflex.
To insert at screen the 
genetic test for Asian 
Americans
The test is not needed at 
Screening

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 3Section # and Name [CONTACT_23688]
Updated the schedule of “CRU 
Confinement”
Day 15 labs was moved to 
Day 16
Vital signs, TSH, T4 and PK 
were all modified on the SOA 
table to accommodate the 
change in CYP3A4 pro: PK 
Sampling Schedule (Days 1-3): 
Vital Signs should include 
(BP/PR/RR) ; Updated TSH & 
free T4 Days 8, 10, and 14 to 
Days 6, 9, 12 and 16 ; Removal of 
pharmacogenomics sampleShould not be continuous on 
day 16 if discharging
Update made to respond to 
PCRU comment
To accommodate the 
change in CYP3A4 proble
and u pdates made per 
PACL
Section 2.3.1 Risk 
AssessmentAdded “ Aplastic anemia and 
agranulocytosis ”Updates made to reflect the 
current design of the study
Section 4.1 Overall 
DesignAdded “ Titration Scheme of 
Carbamazepi[INVESTIGATOR_050] ”Updates made to reflect the 
current design of the study.
Section 5.[ADDRESS_1055043] the 
current design of the study
Section 6.1 Study 
Intervention(s) 
AdministeredUpdate the intervention of 
carbamazepi[INVESTIGATOR_769036].
Section 6.1.[ADDRESS_1055044] Updates made per PACL
Section 6.2 
Preparation, Handling, 
Storage, and 
AccountabilityRemoval of IP Manual Updates made per PACL
Section 6.8 
Concomitant TherapyPermitted/prohibited concomitant 
treatments updatedUpdates made to reflect the 
current design of the study.
Section 8 Study 
Assessments and 
ProceduresRemoval of Section 8.5.1 (Specified 
Genetics)Updates made per PACL
Section 10.2 Appendix 
2Removed “QuantiFERON test” and 
added “HLA -B*-1502 & HLA -A* 
3101”To align with the updates in 
SOA

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 4Section # and Name [CONTACT_19523] 11 Reference Reference #4 -7 added
Removed original reference #4 -6 
related to rifampinTo support the use of 
carbamazepi[INVESTIGATOR_050].
Rifampin was n o longer
used in this study
Minor editorial changes throughout

PF-[ADDRESS_1055045] OF TABLES ................................ ................................ ................................ ................... 10
1. PROTOCOL  SUMMARY ...................................................................................................11
1.1. Sy nopsis ..................................................................................................................11
1.2. Schema ....................................................................................................................16
1.3. Schedule of Activities .............................................................................................17
2. INTRODUCTION ...............................................................................................................21
2.1. Study  Rationa le.......................................................................................................21
2.2. Background .............................................................................................................21
2.2.1. Nonclinical Pharmacology ..........................................................................22
2.2.2. Nonclinical Pharmacokinetics and Metabolism
.........................................22
2.2.3. Nonclinical Safet y
......................................................................................22
2.2.4. Clinical Overview .......................................................................................23
[IP_ADDRESS]. Safet y Overview ........................................................................23
[IP_ADDRESS]. Summary  of PF -
07321332 Pharmacokinetics in Human..........24
2.3. Benefit/Risk Assessment
.........................................................................................24
2.3.1. Risk Assessment .........................................................................................25
2.3.2. Benefit Assessment .....................................................................................28
2.3.3. Overall Benefit/Risk Conclusion ................................................................28
3. OBJECTI
VES AND EN DPOINTS .....................................................................................28
4. STUDY DESIGN .................................................................................................................28
4.1. Overall Design .........................................................................................................28
4.2. Scientific Rationale for Study  Design .....................................................................30
4.2.1. Choice of Contraception/Barrier Requirements .........................................31
4.2.2. Collection of Retained Research Samples ..................................................31
4.3. Justification for Dose ..............................................................................................31
4.4. End of Study  Definition ..........................................................................................32
5. STUDY POPUL ATION
................................ ................................ ................................ ......32
5.1. I nclusion Criteria .....................................................................................................32
5.2. Exclu sion Criteria ....................................................................................................33
5.3. L ifesty le Considerations ..........................................................................................36

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 65.3.1. Meals and Dietary  Restrictions ...................................................................36
5.3.2. Caffeine, Alcohol, and Tobacco .................................................................36
5.3.3. Activity .......................................................................................................37
5.3.4. Contraception ..............................................................................................37
5.4. Screen Failures ........................................................................................................37
6. STUDY INTERVENTIO N(S) AND CONCOMITANT THERAPY .................................37
6.1. Study  Intervention(s) Administered ........................................................................37
6.1.1. Administration ............................................................................................38
6.2.Preparation, Handling, Storage, and Accountability ...............................................38
6.2.1. Preparation and Dispensing ........................................................................39
6.3. Measures to Minimize Bias: Randomization and Blinding .....................................39
6.3.1. Allocation to Study Intervention ................................................................39
6.4. Study  Intervention Compliance ...............................................................................39
6.5. Dose Modification ...................................................................................................40
6.6. Continued Access to Study  Intervention After the End of the Study ...................... 40
6.7. Treatment of Overdose............................................................................................40
6.8. Concomitant Therapy ..............................................................................................40
6.8.1. Rescue 
Medicine .........................................................................................41
7. DI SCONTINUATION O F STUDY INTERVENTION AND PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ...........................................................................41
7.1. Discontinuation of Study  Intervention ....................................................................41
7.1.1. ECG Changes ..............................................................................................42
7.1.2. Potential Cases of Acute Kidney  Injury .....................................................42
7.2. Participant Discontinuation/Withdrawal From the Study ................................ .......[ADDRESS_1055046] to Follow -Up...................................................................................................44
8. STUDY ASSESSMENTS AND PROCEDURES ................................ ............................... 44
8.1. Efficacy  Assessments ..............................................................................................45
8.2. Safet y Assessments .................................................................................................45
8.2.1. Phy sical Examinations ................................................................................45
8.2.2. Vital Signs ..................................................................................................46
[IP_ADDRESS]. Respi[INVESTIGATOR_82218] ........................................................................46

PF-07321332
Protocol C4671014Amendment 1, 02 Jul 2021
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Temperature ..............................................................................46
8.2.3. Electrocardiograms.....................................................................................468.2.4. Clinical Safety La boratory Asse ssments ....................................................47
8.2.5. COVID-19 Specific Assessments...............................................................488.2.6. Pregnancy Testing ......................................................................................488.2.7. Suicidal Ideation and Behavior Risk Monitoring .......................................48
8.3. Adverse Events, Serious Adverse Events, and Other Safety Reporting .................49
8.3.1. Time Period and Frequency for Collecting AE and SAE Information.......49
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety...............................................[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF...................50
8.3.2. Method of Detecting AEs and SAEs ..........................................................508.3.3. Follow-up of AEs and SAEs.......................................................................518.3.4. Regulatory Reporting Requirements for SAEs...........................................518.3.5. Environmental Exposure, Exposure During Pregnancy or 
Breastfeeding, and Occupational Exposure .....................................................51
[IP_ADDRESS]. Exposure During Pregnancy......................................................[IP_ADDRESS]. Exposure During Breastfeeding ................................................[IP_ADDRESS]. Occupational Exposure .............................................................54
8.3.6. Cardiovascular and Death Events...............................................................548.3.7. Disease Related- Events and/or Disease Related- Outcomes Not 
Qualifying as AEs or SAEs..............................................................................[ADDRESS_1055047].............................................................54
[IP_ADDRESS]. Lack of Efficacy........................................................................54
8.3.9. Medical Device Deficiencies......................................................................548.3.10. Medication Errors .....................................................................................54
8.4. Pharmacokinetics ....................................................................................................55
8.4.1. Plasma for Analysis of PF-07321332 and Ritonavir ..................................558.4.2. Plasma Qualitative Metabolite Profiling ....................................................56
8.6. Biomarkers ..............................................................................................................56
8.6.1. Specified Gene Expression (RNA) Research .............................................56
CCI
PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 88.6.2. Specified Protein Research .........................................................................56
8.6.3. Specified Metabolomic Research ...............................................................57
8.7. I mmunogenicit y Assessments .................................................................................57
8.8. Health Economics ...................................................................................................57
9. STATI STICAL CONSI DERATIONS
................................................................................57
9.1. Statistical Hy potheses .............................................................................................57
9.2. Analy sis Sets ...........................................................................................................57
9.3. Statistical Analy ses.................................................................................................57
9.3.1. Other Safet y Analyses ................................................................................58
9.3.2. Statistical Methods for PK Data .................................................................58
9.3.3. Derivation of Pharmacokinetic Parameters Prior to Analy sis....................58
9.4. I nterim Anal yses.....................................................................................................59
9.5. Sample Size Determination .....................................................................................59
10. SUPPORTING DOCUM ENTATION AND OPERATI ONAL 
CONSI DERATIONS
..........................................................................................................61
10.1. Appendix 1: Regulatory , Ethical, and Study  Oversight Considerations ...............61
10.1.1. Regulatory and Ethical Considerations
....................................................61
[IP_ADDRESS]. Reporting of Safety  Issues and Serious Breaches of the 
Protocol or I CH GCP .........................................................................61
10.1.2. I nformed Consent Process ........................................................................62
10.1.3. Data Protection .........................................................................................63
10.1.4. Committees Structure ...............................................................................63
[IP_ADDRESS]. Data Monitoring Committee ...................................................63
10.1.5. Dissemination of Clinical Study  Data ................................ ...................... 63
10.1.6. Data Qualit y Assurance ............................................................................64
10.1.7. Source Documents ....................................................................................66
10.1.8. Study  and Site Start and Closure ................................ .............................. 66
10.1.9. Publication Policy.....................................................................................67
10.1.10. Sponsor’s Qualified Medical Personnel .................................................67
10.2. Appendix 2: Clinical Laboratory  Tests .................................................................69
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ......................................................................70

PF-07321332
Protocol C4671014Amendment 1, 02 Jul 2021
PFIZER CONFIDENTIAL
Page 910.3.1. Definition of AE .......................................................................................70
10.3.2. Definition of an SAE ................................................................................7110.3.3. Recording/Reporting and Follow-up of AEs and/or SAEs During 
the Active Collection Period............................................................................72
10.3.4. Reporting of SAEs....................................................................................76
10.4. Appendix 4: Contraceptive and Barrier Guidance ................................................78
10.4.1. Male Participant Reproductive Inclusion Criteria ....................................7810.4.2. Female Participant Reproductive Inclusion Criteria.................................7810.4.3. Woman of Childbearing Potential ............................................................7910.4.4. Contraception Methods.............................................................................80
10.6. Appendix 6: Liver Safety: Suggested Actions and Follow-Up Assessments .......82
10.7. Appendix 7: ECG Findings of Potential Clinical Concern ...................................8410.8. Appendix 8: Prohibited and Precautionary Concomitant Medications That 
May Result in DDI ....................................................................................................86
10.9. Appendix 9: Abbreviations ...................................................................................[ADDRESS_1055048] OF TABLES
Table 1. Plasma PK Parameters ................................ ................................ .............. 59
Table 2. Protocol -Required Safet y Laboratory  Assessments .................................69

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 111.PROTOCOL SUMMARY 
1.1.Synopsis 
Brief Title: A Phase 1 Study to Estimate the Effects of Carbamazepi[INVESTIGATOR_769037]-07321332/Ritonavir in Healthy  Participants
Rationale
PF-07321332 is a potent and selective inhibitor of the SARS -CoV -2 3CL protease that is 
currentl y being developed as an oral treatment of COVID -19.Ritonavir is a strong CYP3A4 
inhibitor being used to inhibit the metabolism of PF -07321332 in order to increase plasma 
concentrations of PF- 07321332 to values that are anticipate d to be efficacious. 
In vitro and in vivo metabolite profiling suggests that the primary  clearance mechanism for 
PF-07321332 is CYP3A4 mediated oxidation. I n a reaction phenot ypi[INVESTIGATOR_422084], CYP3A4 was predicted to be 
the major contributor (f m= 0.99) to the in vitro oxidative metabolism of PF- 07321332. As 
such, in the FIH stud y, C4671001, the CYP3A4 inhibitor ritonavir was used to enhance the 
exposure of PF- 07321332 in order to achieve plasma levels that are anticipated to be 
efficacious. Preliminary  PK data following multiple oral administrations of 
PF‑07321332/ritonavir at doses of 75/100 mg, 250/100 mg, and 500/[ADDRESS_1055049]  may  also play  a signif icant role in PF -07321332 excretion when 
co-administered with ritonavir, with approximately  32.5% (PF ‑07321332/ritonavir 
500/100 mg) to 64.6% (PF‑07321332/ritonavir 75/100 mg) of the drug excreted unchanged 
in urine across doses at stead y-state, and renal clearance ranging between 3.5 to 4.4 L/h 
across doses. Ritonavir is extensively  metabolized, primarily  by [CONTACT_097]3A4.1Based on 
available data to date, it is possible th at induction of CYP3A4 (ie,carbamazepi[INVESTIGATOR_050]) may lead 
to further decreased exposure sof PF ‑07321332/ritonavir. Therefore, results of this study  will 
provide guidance for dosing with inducers of CYP3A4.
The purpose of this stud y is to estimate the effect of carbamazepi[INVESTIGATOR_050] , a strong inducer of 
CYP3A4 on the PK of PF -07321332/ritonavir in healthy  participants.

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 12Objectives and Endpoints
Objectives Endpoints
Prim ary: Prim ary:
To estimate the effect of carbamazepi[INVESTIGATOR_769038] -07321332 after a single dose of 
PF-07321332 /ritonavir (reference) compared
to the PK of PF -0732133 2after a single dose
of PF -07321332 /ritonavir ,follow ingmultiple
dosing with carbam azepi[INVESTIGATOR_050] (test).Plasma PF -07321332 PK parameters: C max,
AUC inf(or AUC lastif AUC infcannot be reliably 
estimated) .
Secondary: Secondary: 
To estimate the effect of carbamazepi[INVESTIGATOR_769039] a single dose of 
PF-07321332/ritonavir (reference) compared 
to the PK of ritonavir after a single dose of 
PF-07321332/ritonavir ,following multiple
dosing with carbam azepi[INVESTIGATOR_050] (test) .
To evaluate the safety and tolerability of 
PF-07321332 /ritonavir alone and , following 
multiple dosing with carbam azepi[INVESTIGATOR_050] .
To characterize additional PK parameters of 
both PF-0732133 2and ritonavir after a single 
dose of PF -07321332/ritonavir (reference) 
compared to the PK of both PF-0732133 2and 
ritonavir, following multiple dosing with 
carbamazepi[INVESTIGATOR_050] . Plasma ritonavir PK parameters: C max,AUC inf (or 
AUC lastif AUC infcannot be reliably estimated) .
Safety: TEAE s, clinical laboratory tests, vital 
signs, PE,and ECGs.
Plasma PF -07321332 and ritonavir PK 
parameters: T max, AUC last, CL/F, V z/F, and t½, as 
data permit.
Overall Design
Brief Summary
This is a Phase 1, fixed sequence, 2- period study  to estimate the effect of a strong CYP3A4 
inducer , carbamazepi[INVESTIGATOR_050] , on the PK of PF -07321332 and ritonavir in healthy  participants.
A total of approximately 12healthy  male and/or female participants will be enrolled into the 
study . The purpose of this study is to characterize the effects of carbamazepi[INVESTIGATOR_769040]-07321332 300 mg/ritonavir [ADDRESS_1055050] of 2 periods. Period 1
(P1) will include PF-07321332 300mg/ritonavir 100 mg as a single oraldose,andPeriod 2 
(P2) will include a 15-day dosing of carbamazepi[INVESTIGATOR_769041] .Carbamazepi[INVESTIGATOR_769042] [ADDRESS_1055051] of P2 from Days 8 to 1 5.(Section 4.1,Figure 1). On Day  14in the P2 ,
asingle dose of PF -07321332 300 mg /ritonavir [ADDRESS_1055052] 12 hours prior to Day 1 dosing 
in P1and will be required to stay  in the CRU for 18 days and 1 7nights. 
In P1, each enrolled participant will receive a single dose of PF-07321332 300 mg /ritonavir 
100 mg orally . Serial PK samples will be collected up to 48hours after a single dose 
administration to determine PK parameters . 
P2 will begin on Study  Day  3(referred to as P2 Day 1). In general, P2 will include a [ADDRESS_1055053] of P2 from Day s 8 
to 15.On P2 Day 14, a single oral dose of PF-07321332
300mg/ritonavir 100mgwill be administered. Following administration of PF- 07321332
300mg/ritonavir 100 mg , participants will undergo serial PK sampling up to 48hours after 
asingle dose administration to determine PK parameters for both PF- 07321332 and ritonavir . 
Participants will be discharged from the CRU on Day  16 in P2 following completion of all 
assessments. 
Eligible participants will be admitted to the CRU on Day  -1 (at least 12 hours prior to Day 1 
dosing of PF -
07321332 300 mg /ritonavir 100mgon Day 1, P1) and will be confined in the 
CRU for 18 day s and 17nights .On the morning of Day 1(P1), the participants will receive 
asingle dose of PF -[ADDRESS_1055054] -dose forPK 
assessments. Starting in the morning on Day 1(P2),carbamazepi[INVESTIGATOR_050] 100mg BID will be 
administered orall y
on Day s1, 2, and [ADDRESS_1055055] of P2 from Day s 8 to 15.Carbamazepi[INVESTIGATOR_050] (Days 1 -15 [P2]) can be administered with or 
without food on all study d ays except on Study  Day  14 when dosing will be under fasting 
conditions. . There are no water restrictions for carbamazepi[INVESTIGATOR_236568]. On Day 14in P2 , 
asingle dose of PF -07321332 300 mg /ritonavir 100mgwill be administered after fasting at 
least10hours . Serial blood samples at specified intervals will be collected up to 48hours 
post-dose forPK assessments of both PF -07321332 and ritonavir.
Safety  assessments will be performed during Screening , on Day  -1 prior to dosing, and at 
specified time points. PE s, vital sign measurements, and clinical laboratory  tests will be 
conducted ,and AEs will be monitored to assess safety . The total participation time ( eg,CRU 
confinement time for study  procedures) for each participant in this study  is approximately  
18 da ys/ 1 7nights (excluding screening andfollow -up contact ).
A safet y follow
-up call will be made to participants 28 to 35 days from administration of the 
dose of study  intervention.

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 14Number of Participants
Approximately  12participants may be enrolled to study  intervention .
Note: "Enrolled" means a participant, or his or her legally  authorized representative’s, 
agreement to participate in a clinical study following completion of the informed consent 
process and screening . A participant will be considered enrolled if the informed consent is 
not withdrawn prior to participating in an y stud y activity  after screening .Potential 
participants who are screened for the purpose of determining eligibility  for the study , but do 
not pa rticipate in the study, are not considered enrolled, unless otherwise specified b y the 
protocol.
Intervention Groups and Duration
Each participant will be screened to determine eligibility  within [ADDRESS_1055056] 12 hours prior to Day  1 and 
will be required to stay  in the CRU for 18days and 17nights .A safet y follow -up call will be 
made to participants approximately  28 to 35 day s from administration of the final dose of 
study  intervent ion. 
Each enrolled participant will participate in 2 study periods: 
Period 1: 
PF-07321332 300 mg /ritonavir 100mg administered orally as a single dose.
Period 2: Carbamazepi[INVESTIGATOR_050] 100mg BID will be administered orall y on Days 1, 2, and 
3, and then titrate up to [ADDRESS_1055057] of P2 from 
Days8 to 15. 
OnDay 14, participant will receive a single dose of PF-07321332
300mg/ritonavir [ADDRESS_1055058] Follow -
up 
phone call, is approximately  11to 12 weeks.
Data Monitoring Committee or Other Independent Oversight Committee :No
Statistical Methods
A sample size of 12 participants will provide adequate precision to estimate the effects of 
carbamazepi[INVESTIGATOR_769043]- 07321332. The expected widths of the 90% CIswith 80% 
coverage probability  are shown in the following table for a range of possible effects. 

PF-[ADDRESS_1055059] 
(100*Test/Reference)90% CI CIWidth
AUC inf 60%
70%
80%
90%
100%53%, 68%
62%, 79%
71%, 90%
80%, 102 %
88%, 113%15%
17%
20%
22%
25%
Cmax 60%
7
0%
80%
9
0%
100%55%, 65%
65%, 76%
74%, 87%
83%, 97%
92%, 108 %9%
11%
13%
14%
16%
These estimates are based on the assumption that within -participant standard deviations are 
0.[ADDRESS_1055060] 
noncompartmental method of anal ysis. Actual PK sampling times will be used in the 
derivation of PF-07321332 and ritonavir PK parameters. The PF-07321332 and ritonavir 
plasma PK parameters will be summarized descriptively  by [CONTACT_3148]. Plasma concentrations 
will be listed and summarized descriptively  by [CONTACT_769084]. 
Individual participant and summary  profiles (mean and median plots) of the plasma 
concentration time data will be plotted using actual and nominal times, respectivel y. For 
AUC infand C max, box and whisker plots of these parameters will be plotted by  [CONTACT_3148]. 
Drug -Drug Interaction
Natural log transformed AUC inf, AUC lastand C maxof PF-[ADDRESS_1055061]. Estimates of the adjusted mean differences (Test-Reference) and 
corresponding 90% CIs will be obtained from the model. The adjusted mean differences and 
90% CI s for the differences will be exponentiated to provide estimates of the ratio of 
adjusted geometric means (Test/Reference) and 90% CI  for the rati os. 
PF-[ADDRESS_1055062] treatment.

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 16Safety Analysis 
AEs, ECGs, BP, pulse rate , and safety  laboratory  data will be rev iewed and summarized on 
an ongoing basis during the study  to evaluate the safet y of participant s. An y clinical 
laboratory , ECG, BP, and pulse rate abnormalities of potential clinical concern will be 
described. Safet y data will be presented in tabular and/o r graphical format and summarized 
descriptivel y, where appropriate.
1.2.Schema
The following schematic represents the study  design.
Screening
Days -28to -
2Period 1(P1)
(Days 1 and 2)*Period 2(P2)
(Days 1 -16)Follow -up
Days 28 -35
(Reference)
PF-07321332 300mg/ritonavir 
100mg single dose(Test)
Carbamazepi[INVESTIGATOR_050]+: 100mg BID on 
Days 1-3, 200 mg BID on Days 4-
7, and 300 mg BID on Days 8 -15
in P2
+
PF-07321332 300 mg /ritonavir 
100 mg single dose
on Day 14in P2
PK sampling
0-48 hrsPK sampling
0-48 hrs
*P1 includes Day -1.
+.Carbamazepi[INVESTIGATOR_769044] [ADDRESS_1055063] of P2 from Days 8 to 1 5.  

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 171.3. S chedule of Activ ities
P1(PF-07321332/ritonavir alone): Screening -Day 2
The SoA table provides an overview of the protocol visits and procedures. Refer to the STUDY ASSESSMENTS AND 
PROCEDURES section of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol. 
The investigator may  schedule visits (unplanned visits) in addition to those listed in the SoA table, in order to conduct evaluations or 
assessments required to protect the well -being of the participant. 
Visit Identifier
Abbreviations used in this t able may be found in Appendix 9.ScreeningaSchedule for Period 1
Days Relative to Day 1 -28 to -2 Day -1 Day 1 Day 2 Day 3
Informed consent X
CRU confinementbX   
Inclusion/exclusion criteria X X
Medical/medication history (update)cX X
Physical examdX X
Safety laborato ry(including aPTT, PT -INR, Fib rinogen)eX X X
DemographyfX
HBsA b(reflex test), HBcAb, HCVAb ,HBsAgand HIV X
Pregnancy test (WOCBP only) X X
Contraception checkgX X
TSH &Free T 4 X X X
HLA -A*3101 and HLA-B*1502
FSHhX
Urine drug testingiX X
12-lead ECGjX X X
Vital signs (BP/ PR/RR)kX X X
COVID -19 questionnairelX X
COVID -19 testingmX X
COVID -19 check temperaturenX X X X
PF-0732133 2/ritonavir administrationoX
PK Blood Sampling for PF-07321332 and ritonavirpX X X

PF-07321332
Protocol C4671014Amendment 1, 02 Jul 2021
PFIZER CONFIDENTIAL
Page 18Visit Identifier
Abbreviations used in this table may be found in Appendix 9 .ScreeningaSchedule for Period 1
Serious and non-serious AE monitoring X →→ → →
Prior and Concomitant Treatment(s) X →→ → →
Suicicality AssessmentrX
a. Screening will be performed within [ADDRESS_1055064] dose of PF-07321332/ritonavir. 
b. Participants will be admitted to the CRU on Day -1. Safety labs can be performed on the day prior to the start of Period [ADDRESS_1055065] er for the results to be available on Day 3 
start of Period 2. Participants will be discharged on P2 Day 16 following the final assessments. 
c. Medical history will include a history of prior illegal drug, alcohol, and tobacco use, as well as blood donation within prio r 60 days. Medical history will be recorded at 
Screening and updated on Day 1 of Period 1. 
d. A full PE, without genitourinary evaluation will be performed by [CONTACT_769085] 1 of Period 1 only (height and 
weight must be obtained at Screening to obtain BMI for eligibility criteria). A limited PE may be performed at other designated time points at the discretion of the 
investigator.
e. Safety laboratory assessments including urinalysis, hematology, and chemistry will be performed at the indicated timepoints. A ll the safety laboratory samples must be 
collected following at least a [ADDRESS_1055066]. Additional safety laboratory assessments may be performed at any time at the discreti on of the investigator. 
f. Demographics will include participant race, ethnicity, age, and gender during the Screening visit. g. On Screening and Day 1, the investigator or his/her designee will discuss with the participant the need to use highly effective  contraception consistently and correctly 
according to contraception guidelines.
h. For postmenopausal (amenorrheic for at least 12 consecutive months) female participants only.i. Urine drug (mandatory) and alcohol breath test (at discretion of investigator) will be performed at Screening and on Day -1. T hese tests may be performed at any other 
time at the discretion of the investigator. 
j. All ECG assessments (triplicate) will be made after at least a [ADDRESS_1055067] will be performed 
after 4 days (ie, upon completion of 4 × 24 hours in house), or if they develop COVID-[ADDRESS_1055068] daily during residence.o. PF-07321332/ritonavir will be administered orally as a single dose following an overnight fast of at least 10 hours. . p. One (approximately 4 mL) blood sample for PK analysis of PF-07321332 and ritonavir will be taken at the following timepoints: D ay [ADDRESS_1055069]-dose.
 
r. C-SSRS Lifetime/Baseline assessment at S
creening and ET if applicableCCI
C
C
PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 19P1(PF-07321332/ritonavir alone): PK Sampling Schedule (Day 1 – Day 3)
Visit IdentifierTreat ment Period on PK Days
Study DayDay [ADDRESS_1055070] Dose after dosing on
Day 10a0.5 1 1.5 2 4 6 8 12 16 24 48a
Study intervention administration X
PK blood sampling X X X X X X X X X X X X
12-lead ECG X X X X
Vital Signs (BP/ PR/RR) X X X X
a. Predose sample collection.
P2(PF-07321332/ritonavir with carbamazepi[INVESTIGATOR_050] ): Day s 1-16
Visit Identifier
Abbreviations used in this t able may 
be found in Appendix 9 .Schedule for Period 2 Follow -
UpEarly Termination/
Discontinuation
Days Relative to Day 1 Day 
1Day 
2Day 
3Day 
4Day 
5Day 
6Day 
7Day 
8Day 
9Day 
10Day 
11Day 
12Day 
13Day 
14Day 
15Day 
1628-35 
Daysj
CRU confinement               
Safety laboratory (including aPTT, 
PT-INR, Fibr inogen)aX X X X X X
Contraception check X X X
Pregnancy test (WOCBP only) X X
12-lead ECGbX X X X X X X
Vital signs (BP/ PR/RR)cX X X X X X X X X X X
TSH & Free T4 X X X X X X
COVID testing X
COVID -19 check temperaturedX X X X X X X X X X X X X X X X
Carbamazepi[INVESTIGATOR_769045] X X X X X X X X X X X X X X
PF-0732133 2/ritonavir administrationfX
PK Blood Sampling for PF-0732133 2 
andritonavirgX X X X
Serious and non -serious adverse event 
monitoring                X X
Concomitant treatment                 X X
Suicidality assessmenthX              X X

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 20Visit Identifier
Abbreviations used in this t able may 
be found in Appendix 9 .Schedule for Period 2 Follow -
UpEarly Termination/
Discontinuation
Days Relative to Day 1 Day 
1Day 
2Day 
3Day 
4Day 
5Day 
6Day 
7Day 
8Day 
9Day 
10Day 
11Day 
12Day 
13Day 
14Day 
15Day 
1628-35 
Daysj
Discharge from CRUi               X
a. Safety laboratory assessments including urinalysis, hematology and chemistry . All the safety laboratory samples must be collected following at least a [ADDRESS_1055071]. Additional 
safety laboratory assessments may be performed any time at the discretion of the Investigator. 
b. All ECG assessments (triplcate ) will be made after at least a [ADDRESS_1055072] of P 2 from Days 8 to 1 5 (see Figure 1).Carbamazepi[INVESTIGATOR_050] (Days 1 -15 [P2]) can be administered with or w ithout food on all 
study days except on Study Day 14 when dosing will be under fasting conditions . There are no w ater restrictions for carbamazepi[INVESTIGATOR_236568].   
f. PF-07321332/ritonavir will be administered orally as a single dose on P2 Day 14 .
g. One (approximately 4 mL) blood sample for PK analysis of PF-07321332 and ritonavir will be taken at the following timepoints: P2 Day [ADDRESS_1055073]-dose .
h. C-SSRS Lifetime/Baseline assessment at screening, since last visit on D ays1 and [ADDRESS_1055074] occur 28 to 35 days from administration of the final dose of study intervention.
P2(PF-07321332/ritonavir with carbamazepi[INVESTIGATOR_050] ):PK Sampling Schedule (Day s 14-16)
Visit IdentifierTreat ment Period on PK Days
P2 Study DayDay [ADDRESS_1055075] 1stDose 
after Dosing on Day 140a0.5 1 1.5 2 4 6 8 12 16 2448
Study intervention administration X X X
PK blood sampling X X X X X X X X X X X X
12-lead ECG X X X X X
Vital Signs (BP/ PR/RR) X X X X X
a. Predose sample collection.

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 212.INTRODUCTION
PF-07321332 is a potent and selective inhibitor of the SARS -CoV -2 3CL  protease that is 
currentl y being developed as an oral treatment of COVID -19.Ritonavir is a strong CYP3A4
inhibitor being used to inhibit the metabolism of PF -07321332 in order to increase plasma 
concentrations of PF- 07321332 to values that are anticipated to be efficacious.
2.1.Study Rationale 
In vitro and in vivo metabolite profiling suggests that the primary clearance mechanism for 
PF-07321332 is CYP3A4 mediated oxidation. I n a reaction phenot ypi[INVESTIGATOR_422084], CYP3A4 was predicted to be 
the major contributor (f m= 0.99) to the in vitro oxidative metabolism of PF -07321332. As 
such, in the FIH stud y, C4671001, the CYP3A4 inhibitor ritonavir was used to enhance the 
exposure of PF
-07321332 in order to achieve plasma levels that are anticipated to be 
efficacious. Preliminary  PK data following multiple oral administrations of 
PF‑07321332/ritonavir at doses of 75/100 mg, 250/100 mg, and 500/[ADDRESS_1055076]  may  also play  a significant role in PF -07321332 excretion when 
co-administered with ritonavir, with approximately  32.5% (PF‑07321332 500mg/ritonavir 
100 mg) to 64.6% (PF ‑07321332 75 mg /ritonavir 100 mg) of the drug excreted unchanged in 
urine across doses at steady -state, and renal clearance ranging between 3.5 to 4.4 L /h across 
doses. Ritonavir is extensively  metabolized, primarily  by [CONTACT_097]3A4.1Based on available data 
to date, it is possible that induction of CYP3A4 (ie,carbamazepi[INVESTIGATOR_050]) may lead to further 
decreased exposure sof PF ‑07321332/ritonavir. Therefore, results of this study  will provide 
guidance for dosing with ind ucers of CYP3A4.
The purpose of this stud y is to estimate the effect of a strong inducer ofCYP3A4 , 
carbamazepi[INVESTIGATOR_769043]- 07321332/ritonavir in healthy  participants.
2.2.Background 
In December 2019, COVID -[ADDRESS_1055077] 
SARS -CoV -23CLpro(Ki = 0.[ZIP_CODE] µM) in a biochemical enz ymatic assay . Since the 
3CLprofrom human coronaviruses are structurally  similar and share a high degree of 
conservation at th e active site of the enzy me, the ability  of PF -07321332 to inhibit the 
3CLproof other coronaviruses (SARS -CoV -1 and HCoV -229E, MERS, HCoV -OC43, 
HCoV -HKU1, and HCoV- NL63) was also confirmed, indicating a potential for broad 
spectrum anti -coronavirus activi ty. The coronavirus 3CL  protease is a virally  encoded 
enzy me that is critical to the SARS -CoV -2 replication cy cle, analogous to other obligatory  
virally  encoded proteases (eg ,HIV Protease, HCV Protease).3PF-[ADDRESS_1055078]  for clearance of 
PF-07321332 in vitro in liver microsomes (mouse, rat, hamster, rabbit, monkey , and human), 
hepatocy tes (rat, monkey, and human), and in vivo in rat and monkey  after repeat oral dosing 
(Study PF-07321332_09Nov20_084546). In a reaction phenoty pi[INVESTIGATOR_422085], CYP3A4 was predicted to be the 
major contributor (f m= 0.99) to t he in vitro oxidative metabolism of PF- 07321332. No 
significant CYP3A5 contribution is expected to the metabolism of PF -07321332. 
(Study PF-07321332_21Nov20_072016). Urinary excretion of PF -07321332 following 
single IV or oral doses in rats was approximate ly 11%, suggesting minor urinary  
contributions to the overall elimination of PF-07321332. 
Additional information of the nonclinical PKand metabolism of PF -[ADDRESS_1055079] dose administered (1000 mg/kg 
and 600 mg/kg in the rat and monkey  studies, respectivel y).PF-
07321332-related
non-adverse, test article -related clinical findings included sporadic occurrence of emesis with 
slight body  weight decreases in monkey s. Monitorable and reversible clinical pathology  
findings included those possibly
 suggestive of low -grade inflammation (in rat s and monkey s) 
or alterations in the coagulation pathway s (in rats only ) without clinical or microscopic 
correlates. Other non-adverse clinical pathology  findings were likel y due to the emesis and 
subsequent deh ydration in monkeys. In rats administered 100 0mg/kg/day , lower mean 
absolute and relative heart weights (females) and higher absolute and relative liver weights 
(both sexes) were observed relative to controls. The lower heart weights had no microscopic 
correlates and were fully  reversed at the end o f the 2 -week recovery  period. Higher liver 
weights correlated with reversible, non-adverse microscopic findings of minimal to mild 
severit y in the liver and thyroid gland consistent with adaptive changes related to microsomal 
enzy me induction.
PF-
07321332 was not  mutagenic or clastogenic in in vitro genetic toxicity  studies and 
was negative in the in vivo rat micronucleus assay  incorporated into the GLP 
repeat -dose rat toxicity  study . 

PF-07321332
Protocol C4671014Amendment 1, 02 Jul 2021
PFIZER CONFIDENTIAL
Page 23•The nonclinical studies performed adequately support the oral administration of 
PF-07321332 in the clinic for up to 14 days.
Further details of the nonclinical safety program are provided in the current IB.2.2.4. Clinical Overview
Safety, tolerability and pharmacokinetics of PF-07321332 in healthy adult participants is 
currently being explored in an ongoing Phase 1 FIH study (C4671001). Study C4671001 is a four-part study consisting of SAD (PART-1), MAD (PART-2), relative bioavailability/food effect (PART-3), and metabolism and excretion study (PART-4). PART-[ADDRESS_1055080] of an oral tablet formulation. PART-4 is an open-label, non-randomized, single period to evaluate the metabolism and excretion of PF-07321332.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CCI
CCI
PF-07321332
Protocol C4671014Amendment 1, 02 Jul 2021
PFIZER CONFIDENTIAL
Page 242.3. Benefit/Risk Assessment
•PF-07321332/ritonavir alone or in combination with carbamazepi[INVESTIGATOR_769046]. This study is 
designed primarily to generate safety, tolerability, and pharmacokinetic data for further clinical development.
More detailed information about the known and expected benefits and risks and reasonably 
expected adverse events of PF-07321332 may be found in the IB which is the SRSD for this study. The SRSDs for ritonavir and carbamazepi[INVESTIGATOR_769047].CCICCI
PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 252.3.1. Risk Assessment
Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Study Intervention(s): PF-07321332
Emesis Sporadic emesis were observed at ≥100 mg/kg/day of PF -
07321332 in the 15 -day NHP -toxicology study (See IB). 
Based on preliminary data, no emesis was observed in the 
FIHStudy C4671001 at single doses of PF-07321332 up to 
1500 m g alone and up to 750 mg administered with ritonavir 
(100 mg at -12h, 0h,12h), and at repeated daily doses 
administered orally for 10days of up to [ADDRESS_1055081] in rat neuronal and pulmonary endpoints 
were observed in rat toxicology study at the high dose level 
(1000 mg/kg as single dose; See IB). Based on preliminary 
data, no AEs su ggestive of neuronal or pulmonary effects 
were observed in the FIH Study C4671001 at single doses of 
PF-07321332 up to 1500 mg alone and up to 750 mg 
administered with ritonavir (100 mg at -12h, 0h,12h), and at 
repeated daily doses administered orally for 10days of up to 
500mg PF -[ADDRESS_1055082]. 
Hem odynamic effects Low level inflammation (increase in fibrinogen) in 15 -day 
NHP toxicology study and changes in platelets, globulin and 
albumin/globulin ratio and coagulation system (increase in 
PT and aPTT) in 14 day rat toxicology study (See IB). No 
relevant laboratory ch anges in inflammatory markers have 
been observed in the FIH Study C4671001 at single doses of 
PF-07321332 up to 1500 mg alone and up to 750 mg 
administered with ritonavir (100 mg at -12h, 0h,12h), and at 
repeated daily doses administered orally for 10days of up to 
500mg PF -07321332 BID with 100 mg ritonavir BID.Fibrinogen, platelets, PT -INR and aPTT, albumin 
and total proteins will be monitored. 

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 26Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Thyroid function studies In 14 day rat toxicology study at high dose of PF-07321332
(1000 mg/kg/day) thyroi d gland changes observed w ere of 
low severity and without evidence of tissue damage. In the 
FIH Study C4671001 , 3participants had TEAEs of elevated 
TSH levels across treatment groups (PF -07321332 or 
placebo w ith ritonavir 100 mg BID) in the MAD part of th e 
study. There was no clinical correlation w ith these TSH 
changes and free T4 remained w ithin reference range at all 
times.TSH and free T4 will be evaluated to monitor 
thyroid function
Study Intervention(s): Ritonavir
Gastrointestinal disturbances (including 
diarrhea, nausea, vomiting and 
abdominal pain).Frequently reported adverse reaction in HIV patients at 
600mg BID.Lower dose of 100 mg twice daily is used in this 
study. There will be close observation of AEs. If 
needed, anti -emetics may be pr ovided. 
Neurological disturbances (eg, 
paresthesia, including oral paresthesia, 
dysgeusia and dizziness).Frequently reported adverse reaction in HIV patients at 
600mg BID.Lower dose used in this study. There w ill be close 
observation of AEs. 
Rash ( most commonly reported as 
erythematous and maculopapular, 
followed by [CONTACT_108135]).Frequently reported adverse reaction in HIV patients at 
600mg BID.Lower dose used in this study. There w ill be close 
observation of AEs and monitoring through 
targeted physi cal exams. If needed, palliative care 
may be provided. 
Fatigue/Asthenia Frequently reported adverse reaction in HIV patients at 
600mg BID.Lower dose used in this study. There w ill be close 
observation of AEs and monitoring through 
targeted physical exa ms.
Limited case reports of renal toxicity Although ritonavir therapy is not generally considered 
nephrotoxic, a limited number of cases of acute kidney 
injury secondary to ritonavir have been reported post -
marketing in HIV patients.Lower dose used in th is study. There w ill be close 
observation of AEs and renal function.

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 27Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Study Intervention (s): Carbam azepi[INVESTIGATOR_769048], including TEN 
and SJS.These reactions are estimated to occur in [ADDRESS_1055083] 
found a strong association between the risk of developi[INVESTIGATOR_769049]/TEN and the presence of HLA- B*1502, an inherited 
allelic variant of the HLA -B gene thatis found almost 
exclusively in patients with ancestry across broad areas of 
Asia. Exclusion criteria includes genetic testing for the 
HLA -B*1502 allele. There w ill be close 
observation of AEs and monitoring through 
targeted physical exams , such as gum and oral 
mucosa, etc . If needed, palliative care may be 
provided.
Aplastic anemia and agranulocytosis Data from a population -based case -control study 
demonstrate that the risk of developi[INVESTIGATOR_769050] 5 -8 
times greater than in the general population. How ever, the 
overall risk of these reactions in the untreated general 
population i s low, approximately 6patients per one million 
population per year for agranulocytosis and 2patients per 
one million population per year for aplastic anemia.There w ill be close observation of AEs and 
monitoring through targeted physical exams and 
safety laboratory testing .
Increased risk of suicidal thoughts or 
behavior in patients taking these drugs 
for any indication.The finding of increased risk with AEDs of varying 
mechanisms of action and across a range of indications 
suggests that the risk applies to all AEDs used for any 
indicationC-SSRS testing at baseline in P1 and P2 Day 16; 
participants can be monitored as they are in 
house, ad- hoc monitoring after discharge and 
during follow -up after 28 -35 days.

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 282.3.2. Benefit Assessment
PF-07321332/ritonavir and carbamazepi[INVESTIGATOR_769051] y clinical benefit to healthy 
participants in this study . Any  anticipated benefit to participants would be in terms of 
contribution to the process of developi[INVESTIGATOR_007] a new therap y in an area of unmet medical need.
2.3.3. Overall Benefit /Risk Conclusion
PF-07321332/ritonavir and carbamazepi[INVESTIGATOR_769052] .Taking into account the measures taken to minimize risk to 
participants of this study , the potential risks identified in association with administration of 
PF-07321332/ritonavir and carbamazepi[INVESTIGATOR_769053], in terms of 
contribution to the process of developi[INVESTIGATOR_007] a new therap y in an area of unmet medical need.
3.OBJECTIVES AND ENDPO INTS
Objectives Endpoints
Prim ary: Prim ary:
To estimate the effect of carbamazepi[INVESTIGATOR_769054] -07321332 after a single dose of 
PF-07321332/ritonavir (reference) compared 
to the PK of PF -0732133 2after a single dose 
of PF -07321332/ritonavir, follow ing multiple 
dosing with carbam azepi[INVESTIGATOR_050] (test) .Plasma PF -07321332 PK parameters: C max,
AUC inf (or AUC lastif AUC infcannot be reliably 
estimated) .
Secondary: Secondary: 
To estimate the effect of carbamazepi[INVESTIGATOR_769055] a single dose of 
PF-07321332/ritonavir (reference) compared
to the PK of ritonavir after a single dose of 
PF-07321332/ritonavir, following multiple
dosing with carbam azepi[INVESTIGATOR_050] (test) .
To evaluate the safety and tole rability of 
PF-07321332 /ritonavir alone and , following 
multiple dosing with carbam azepi[INVESTIGATOR_050] .
To characterize additional PK parameters of 
both PF -0732133 2and ritonavir after a single 
dose of PF -07321332/ritonavir (reference)
compared to the PK of both PF -0732133 2and 
ritonavir, following multiple dosing with 
carbamazepi[INVESTIGATOR_050] . Plasma ritonavir PK parameters: C max, AUC inf (or 
AUC lastif AUC infcannot be reliably estimated) .
Safety: treatment -emergent adverse events, 
clinical laboratory tests, vital signs, PE, and 
ECGs.
Plasma PF -07321332 and ritonavir PK 
parameters: T max, AUC last, CL/F, V z/F, and t ½, as 
data permit.
4.STUDY DESIGN
4.1.Overall Design
This is a Phase 1, fixed sequence, 2- period study to estimate the effect of a strong CYP3A4 
inducer, carbamazepi[INVESTIGATOR_050] , on the PK of PF-[ADDRESS_1055084] of 2 periods. P1will include PF -07321332 300 mg /ritonavir [ADDRESS_1055085] of P2 from 
Days 8 to 1
5(Figure 1) . A total of approxim ately 12 healthy  male and/or female participants 
will be enrolled into the study . The treatment will consist of a single fixed sequence. 
Participants who discontinue from the stud y may be replaced at the sponsor’s discretion in 
collaboration with the Inves tigator . 
Figure 1. Titration Scheme of Carbamazepi[INVESTIGATOR_769056] y is to characterize the effects of carbamazepi[INVESTIGATOR_769057] -
07321332 300 mg /ritonavir 100 mg. Safety  and tolerability  will also be assessed 
throughout the duration of the study .
Health y participants will be screened to determine eligibility  within 28 day s prior to study  
treatment. Medical history and results of PE, phy sical measurements, vital signs, 12 -lead 
ECGs (triplicate) , and cli nical laboratory  evaluations will determine eligibility . Participants 
will report to the CRU at least 12 hours prior to Day 1 dosing in P1 and will be required to 
stay in the CRU for 18days and 17nights. 
In P1, e ach enrolled participant will receive a single dose PF-07321332 300 mg /ritonavir
100mgadministered orally as a single dose. Serial PK samples will be collected up to 48
hours after single dose administration to determine PK parameters. 
P2will begin on Study  Day  3(referred to as P2 Day  1).In general, P2 will include a [ADDRESS_1055086] of P2 from Day s 8 to 15 (Figure 1 ). On Day  14 in P2, a single oral dose of PF -

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page [PHONE_16057] 300 mg/ritonavir [ADDRESS_1055087] Follow -up 
phone call, is approximately  11to12weeks.
Eligible participants will be admitted to the CRU on Day  -1 (at least 12 hours prior to Day  1 
dosing of PF -
07321332 300 mg /ritonavir 100 mg on Day 1, P1 ) and will be confined in the 
CRU for 1
8 day s and 17 nights . On the morning of Day 1 (P1), the participants will receive a 
single oral dose of 
PF-[ADDRESS_1055088] -dose for PK 
assessments. Starting in the morning on Day 1 (P2), carbamazepi[INVESTIGATOR_050] 100 mg BID ( no fasting 
is required) will be administered orall y on Days 1, 2, and 3, and then titrate up to [ADDRESS_1055089] of P2 from Day s 8 to 1
5.Carbamazepi[INVESTIGATOR_050] (Day s 1-15 [P2]) can be 
administered with or without food on all s tudy days except on Study  Day  14 when dosing 
will be under fasting conditions. There are no water restrictions for carbamazepi[INVESTIGATOR_236568] .
On P2 Day  14,a single dose of PF- 07321332 300 mg /ritonavir 100mgwill be administered 
as a single dose after fast ingat least 10 hours. Serial blood samples at specified intervals will 
be collected up to 48 hours after single dose adminstration for PK assessments of both PF-
07321332 and ritonavir.
Safety  assessments will be performed during Screening, on Day  -1 prior to dosing, and at 
specified time points. PE s, vital sign measurements, and clinical laboratory  tests will be 
conducted, and AEs will be monitored to assess safety . The total participation time (eg, CRU 
confinement time for study  procedures) for each particip ant in this study  is approximately  
18days/17nights (excluding screening and follow -up contact ).
A safet y follow
-up call will be made to participants approximately  28 to 35 day s from 
administration of the final dose of study  intervention .
4.2.Scientific 
Rationale for Study Design
In vitro and in vivo metabolite profiling suggests that the primary  clearance mechanism for 
PF-07321332 is CYP3A4 mediated oxidation (fm= 0.99) . As such, in the FIH study , 
C4671001, the CYP3A4 inhibitor ritonavir was used to enh ance the exposure of 
PF-
07321332 in order to achieve plasma levels that are anticipated to be efficacious. 
Preliminary  PK data following multiple oral administrations of PF -07321332/ritonavir at 
doses ranging from 75/100 mg to 500/[ADDRESS_1055090]  may  also 
play a significant role in PF -
07321332 excretion when co- administered with ritonavir (32.5% 
to 64.6% of the drug excreted unchanged in urine across doses at stead y-state).Ritonavir is 
extensively  metabolized, primarily  by [CONTACT_097]3A4 .1Mechanisticall y, inhibition of CYP3A4 
could further decrease the metabolism of PF-07321332 and ritonavir , and thereb y increase 
circulating exposures. Based on available data to date, it is possible that induction of 

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 31CYP3A4 (ie,carbamazepi[INVESTIGATOR_050]) may lead to further decreased exposure of 
PF‑07321332/ritonavir. The objective of this study  is to evaluate the effect of a probe 
CYP3A4 inducer , carbamazepi[INVESTIGATOR_769058] y-state on a single dose of PF-07321332 /ritonavir .
The inducer to be utilized in this study  is carbamazepi[INVESTIGATOR_050] , which is a strong inducer of 
CYP3A. For these characteristics, along with its safety  profile, carbamazepi[INVESTIGATOR_769059] a perp etrator drug for CYP3A induction PK drug interaction studies .4,5Since 
PF-07321332 and ritonavi raresubstrate s of CYP3A, concomitant administration with 
carbamazepi[INVESTIGATOR_769060]-07321332/ritonavir may lead to decrea sedsystemic exposure s
ofPF-07321332 and ritonavi r. This may  require PF-07321332/ritonavir dose adjustment 
when it is utilized with medications that are strong CYP3A inducers . Results of this study
willprovide guidance for dosing recommendations with inducers of CYP3A4. 
4.2.1. Choice of Contracep tion/Barrier Requirements 
Human reproductive safety  data are 
limited for PF-07321332, but there is no suspi[INVESTIGATOR_143355] y based on the intended pharmacology of the compound. Therefore, the 
use of a highl y effective method of contraception is required (see 
Appendix 4 ).
4.2.2. Collection of Retained Research Samples
Retained Research Samples will be collected and stored for further anal yses which may , for 
example, provide greater understanding of the study intervention.
4.3.Justification for Dose
A dose of 300 mg PF -07321332 , pharmacokinetically  enhanced with 100 mg ritonavir, to be 
administered as a single dose is planned in this study . This is the anticipated Phase 2/3 dose 
of PF-07321332/ritonavir of 300/[ADDRESS_1055091] been no deaths or serious adver se events or 
S[LOCATION_003]Rs reported. Based on review of preliminary (unaudited) data, all reported adverse 
events have been of mild intensity . There were no clinically  meaningful findings in vital 
signs, ECG , or potential Hy ’s Law cases reported during thestudy .
The dose of ritonavir to be used in this study  is [ADDRESS_1055092] been used in 
adults . Carbamazipi[INVESTIGATOR_769061] (such as trigeminal 
neuralgia ). Considering the dose of carbamazepi[INVESTIGATOR_769062] D DI study , both the titration schedule and the maximum dose of [ADDRESS_1055093] completed the study  if he/she has completed all parts of 
the study ,including the last scheduled procedure shown in the SoA .
5.STUDY POPULATION
This study  can fulfill its objectives only  if appropriate participant s are enrolled. The 
following eligibility  criteria are designed to select participant s for whom participation in the 
study  is considered appropriate. All relevant medical and nonmedical conditions should be 
taken into consideration when deciding whether a particular participant is suitable for this 
protocol .
Prospective approval of protocol deviations to recruitment and enrol lment criteria ,also 
known as protocol waivers or exemptions, is not permitted .
5.1.
Inclusion Criteria
Participants are eligible to be included in the study onl y if all of the following criteria appl y:
Age and Sex :
1.Male or female p articipants must be 18 to 60 years of age, inclusive, at the time of 
signing the ICD .
Type of Participant and Disease Characteristics:
2.Male and female p articipants who are overtl y healthy as determined b y medical 
evaluation including medical history , PE, laboratory  tests, and cardiac assessment .
Refer to Appendix 4forreproductive criteria for male (Section 10.4.1 )and 
female (Section 10.4.2 )participant s
3.Participants who are willing and able to compl y with all scheduled visits, treatment 
plan, laboratory  tests, and other study  procedures.
4.Female participa ntsof childbearing potential must have a negative (urine or serum) 
pregnancy  test.
Weight: 
5.BMI of 17.5 to 30 .5kg/m2; and a total body  weight >50 kg (110 lb).

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 33Informed Consent:
6.Capable of giving signed informed consent as described in Appendix 1 ,which 
includes compliance with the requirements and restrictions listed in the I CDand in 
this protocol.
5.2. Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions:
1.Positive test (RT- PCR) result for SARS -CoV -2 infection at the time of Screening or 
Day -1.
2.Evidence or history  of clinically  significant hematological, ren
al, endocrine, 
pulmonary , gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic al, or 
allergic disease (including drug allergies, but excluding untreated, as ymptomatic, 
seasonal allergies at the time of dosing ).
3.Clinically relevant abnormaliti es requiring treatment (eg ,acute my ocardial infarction, 
serious tach y or brad yarrhythmias) or indicating serious underl ying heart disease 
(eg,prolonged PR or QT interval, cardiomy opathy, underly ing structural heart 
disease, Wolff Parkinson –White sy ndrome ). 
4.Any condition possibly  affecting drug absorption (eg, gastrectomy , cholecy stectom y
)
5.History  of HIV infection, hepatitis B, or hepatitis C; positive testing for HIV, HBsAg, 
HBcAb, or HCVAb. Hepatitis B vaccination is allowed.
6.Any conduction abnormality  (including but not specific to left or right complete 
bundle branch block, or AV block [2nd degree or higher] ).
7.Subjects shown to carry  or be positive for HL A -B* 1502 and HLA -A*3101
(genoty pi[INVESTIGATOR_769063]/ marker srelated with carbamazepi[INVESTIGATOR_050] -associated Stevens–Johnson 
syndrome or toxic epi[INVESTIGATOR_23936])
8.History  of aplastic anemia and agranulocy tosis
9.History  of bone marrow suppression
10.History  of a amixed seizure disorder that includes aty pi[INVESTIGATOR_32539] (could 
induce frequency  of generalized convulsion.), 
11.
Other medical or psychiatric condition including recent (within the past year) or 
active suicidal ideation/behavior or laboratory  abnormality  or other conditions or 
situations related to COVID -19 pandemic (eg ,Contact [CONTACT_216478], residence, 

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 34or travel to an area with high incidence) that may  increase the risk of study 
participation or, in the investigator’s judgment, make the particip ant inappropriate for 
the study .
Prior/Concomitant Therapy:
12.Use of prescription or nonprescription drugs and dietary and herbal supplements 
within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study  
intervention. ( Refer to Section 6.8Concomitant Therap y for additional details ).
13.Current use of any prohibited concomitant medication(s) or those unwilling/unable to 
use a permitted concomitant medication(s). Refer to Section 6.8Concomitant 
Therap y.
14. Participants who have been vaccinated with COVID- [ADDRESS_1055094] week 
(7 day s)of dosing or are to be vaccinated with these vaccines at an y time during the 
study  confinement period.
15.Herbal supplements and ho rmonal methods of contraception (including oral and 
transdermal contraceptives, injectable progesterone, vaginal ring, and postcoital 
contraceptive methods) and hormone replacement therap y must have been 
discontinued at least [ADDRESS_1055095] dose of study  
treatment.
16.Participants taking MAO Isshould discontinue MA O
Ifor a minimum of 14 days prior 
to dosing in the current study .
Prior/Concurrent Clinical Study Experience:
17.Previous administration with an investigational drug within 30 days (or as determined 
by [CONTACT_19970]) or 5half-lives preceding the first dose of study  intervention 
used in this study (whichever is longer). Investigation drug does not include EUA 
vaccines.
Diagnostic Assessments:
18.A positive urine drug test.
19.Screening supi[INVESTIGATOR_30991] ≥140 mmHg (s ystolic) or ≥90mmHg (diastolic), following at 
least [ADDRESS_1055096]. If BP is ≥140 mmHg (s ystolic) or ≥ 90mmHg
(diastolic), the BP should be repeated 2 more times and the average of the 3 BP 
values should be used to determine the participant ’s eligibility .
20.Baseline 12-lead ECG (triplicate) thatdemonstrates clinically relevant abnormalities 
thatmay affect participant safety or interpretation of study results (eg, baseline QTc F 

PF-07321332
Protocol C4671014Amendment 1, 02 Jul 2021
PFIZER CONFIDENTIAL
Page 35interval >[ADDRESS_1055097]-degree AV block, or serious bradyarrhythmias or tachyarrhythmias). If the baseline uncorrected QT interval is >450 msec, this interval should be ratecorrected- using the Fridericia method and the resulting QTcF should be used for decision making and reporting. If QTcF exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 2 more times and the average of the 3 QTcF or QRS values should be used to determine the participant’s eligibility. Computerinterpreted- ECGs should be overread by a physician experienced in reading ECGs before excluding a participant.
21. Participants with ANY of the following abnormalities in clinical laboratory tests at 
screening, as assessed by [CONTACT_769086]- laboratory and confirmed by a single 
repeat test, if deemed necessary: 
•AST orALT level >1.0 × ULN;
•Total bilirubin level ≥1.5 × ULN; participants with a history of Gilbert's 
syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is ≤ULN.
•eGFR <90 mL/min/1.73m
2(10%) based on the CKD-EPI [INVESTIGATOR_769064]:
22. History of alcohol abuse or binge drinking and/or any other illicit drug use or 
dependence within 6 months of Screening. Binge drinking is defined as a pattern of 5 (male) and 4 (female) or more alcoholic drinks in about 2 hours. As a general rule, alcohol intake should not exceed 14 units per week (1 unit = 8 ounces [240 mL] beer, 1 ounce [30 mL] of 40% spi[INVESTIGATOR_107060] 3 ounces [90 mL] of wine).
23. Blood donation (excluding plasma donations) of approximately 1 pi[INVESTIGATOR_11731] (500 mL) or 
more within [ADDRESS_1055098] of the 
study, site staff otherwise supervised by [CONTACT_093], and their respective family members. 
27. History of sensitivity reactions to ritonavir or carbamazepi[INVESTIGATOR_769065]-07321332, ritonavir, or carbamazepi[INVESTIGATOR_050].
PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 365.3.Lifestyle Considerations
The following guidelines are provided:
5.3.1. Meals and Dietary Restri ctions
Participants must abstain from all food and drink (except water) at least 4 hours prior 
to any  safety laboratory  evaluations and 10 hours prior to administration
PF-07321332/ritonavir and the collection of the predose PK sample and morning 
PF-
07321332/ritonavir administration on Day  1(P1) andDay 14(P2).
Carbamazepi[INVESTIGATOR_050] (Day s 1
-15 [P2]) can be administered with or without food on all 
study  days except on Study  Day  14 when dosing will be under fasting conditions.
There are no water restrictions for carbamazepi[INVESTIGATOR_236568] . 
On day s where no PK sampling is required, participants can resume normal intake of
both food and water.
Noncaffeinated drinks (except grapefruit or grapefruit related -citrus fruit juices—see 
below) may  be consumed with meals and the evening snack .
Lunch canbe provided approximately  4hours after dosing the last dose of the 
morning of either carbamazepi[INVESTIGATOR_769066] - 07321332/ritonavir.  
Dinner canbe provided approximately  9to [ADDRESS_1055099] dose of the 
morning of either carbamazepi[INVESTIGATOR_769066] -07321332/ritonavir.  
An evening snack may be permitted .
Participants will refrain from consuming red wine, grapefruit ,or grapefruit
related -citrus fruits (eg, Seville oranges, pomelos, fruit juices) from [ADDRESS_1055100] dose of study  intervention until collection of the final PK blood sample. 
While participants are confined, their total daily  nutritional composition should be 
approximately  55% carbohy drate, 30% fat ,and 15% protein. The dail y caloric intake 
per participant should not exceed approximately  3200 kcal.
5.3.2.
Caffeine, Alcohol, and Tobacco
Participants will abstain from caffeine containing products for 24 hours prior to the 
start of dosing until collection of the final PK sample of each study  period. 
Participants will abstain from alcohol for 24 hours prior to admission (except as 
stated above for red wine) to the CRU and continue abstaining from alcohol until 
collection of the final PK sample of each study  period. Par ticipants may  undergo an 
alcohol breath test or blood alcohol test at the discretion of the investigator.

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 37Participants will abstain from the use of tobacco or nicotine containing products for 
24 hours prior to dosing and during confinement in the CRU.
5.3.3. Activity
Participants will abstain from strenuous exercise (eg, heav y lifting, weight training, 
calisthenics, aerobics) for at least 48 hours prior to each blood collection for clinical 
laboratory  tests. Walking at a normal pace will be permitted.
5.3.4. Contracepti on 
The investigator or his or her designee, in consultation with the participant, will confirm that 
the participant has selected an appropriate method of contraception for the individual 
participant and his or her partner(s) from the permitted list of contraception methods (see 
Appendix 4 Section 10.4.4 ) and will confirm that the participan t has been instructed in its 
consistent and correct use. At time points indicated in the SoA, the investigator or designee 
will inform the participant of the need to use highly  effective contraception consistently  and 
correctly  and document the conversation and the participant’s affirmation in the participant’s 
chart (participants need to affirm their consistent and correct use of at least 1 of the selected 
methods of contraception) considering that their risk for pregnancy  may  have changed since 
the last visit. I n addition, the investigator or designee will instruct the participant to call 
immediately  if the selected contraception method is discontinued or if pregnancy  is known or 
suspected in the participant or partner.
5.4.Screen Failu res
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently  enrolled in the study . Screen failure data are collected and remain as 
source and are not reported on the CRF.
Individuals who do not meet the criteria for participation in this study  (screen failure) may  be 
rescreened. 
6.STUDY INTERVENTION(S) AND CONCOMITANT THERAPY
Study  intervention is defined as any  investigational intervention(s), marketed product(s), 
placebo, medical device(s) , or s tudy procedure(s) intended to be administered to a study  
participant according to the study  protocol.
For the purposes of this protocol, study  intervention refers to PF-07321332/ritonavir and 
carbamazepi[INVESTIGATOR_050] .
6.1.
Study Intervention(s) Administered
PF-07321332 100mg tablet will be provided b y [COMPANY_007] 
Ritonavir 100 mg tablets will be supplied locally  by [CONTACT_47365]
Carbamazepi[INVESTIGATOR_050] 100mg ER tablet will be supplied locally  by [CONTACT_769087]-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 38CRU will use 2 × 100 mg tablet sfor 200 mg dose and 3 ×[ADDRESS_1055101] 10 hours, participant s will receive 
300 mg PF-07321332 (as 3 × 100 mg tablet), administered orall y with 100 mg ritonavir (as 
1 × 100 mg tablet) adm inistered orall yas a single dose starting at approximately  0800 hours 
(plus or minus 2 hours) .PF-
07321332 and ritonavir will be dosed simultaneously  (within no 
more than 5 minutes of each other). 
Investigator site personnel will administer with ambient temperature water to a total volume 
of approximately  240 mL. Study  intervention will be administered according to the protocol .
In Period 2, on Day s 1through 15, inclusive, participants will receive carbamazepi[INVESTIGATOR_050]
(starting 100 mg BID and titrating up to 300mgBID,atapproximately  0800 hours (plus or 
minus 2 hours). Carbamazepi[INVESTIGATOR_050] (Day s 1-15 [P2]) can be administered with or without food 
on all study  days except on Study  Day  [ADDRESS_1055102] 
of P2 from Day s 8 to 15.
Approximately  15-30 min after the carbamazepi[INVESTIGATOR_67910], on P2 Day 14, participants will 
receive 300 mg PF
-07321332 (as 3 ×100 mg tablet), administered orally  with 100 mg 
ritonavir (as 1 × 100 mg tablet) administered orally , starting at approximately  0815 to 
0830
hours (plus or minus 10 min ). PF -07321332 and ritonavir will be dosed simultaneously  
(within no more than 5 minutes of each other )
.
There are no water restrictions for carbamaze pi[INVESTIGATOR_769067].
6.2.Preparation , Handling , Storage , and Accountability
1.
The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study  intervention sreceived and an y 
discrepancies ar e reported and resolved before use of the study  intervention. 
2.Only  participants enrolled in the study  may  receive study  intervention and only  
authorized site staff may  supply  or administer study  intervention. All study  
interventions must be stored in a se cure, environmentally  controlled, and monitored 
(manual or automated recording) area in accordance with the labeled storage 
conditions with access limited to the investigator and authorized site staff. At a 
minimum, daily  minimum and maximum temperatures f or all site storage locations 
must be documented and available upon request. Data for nonworking day s must 

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 39indicate the minimum and maximum temperature ssince previousl y documented for 
all site storage locations upon return to business.
3.Any storage conditions stated in the SRSD will be superseded by  [CONTACT_78254].
4.Study  interventions should be stored in their original containers.
5. The investigator, institution, or the head of the medical institution (where appl icable) 
is responsible for stud y intervention accountability, reconciliation, and record 
maintenance (ie, receipt, reconciliation, and final disposition records) , such as the 
IPAL or sponsor -approved equivalent .All study  intervention swill be accounted for 
using a study  intervention accountabilit y form/record.
6.2.1. Preparation and Dispensing
Within this protocol, preparation refers to the investigator site activities performed to make 
the study  intervention ready  for administration or dispensing to the participant by [CONTACT_216479]. Dispensing is defined as the provision of study  intervention , concomitant treatments, 
and accompan ying information by  [CONTACT_22806](s) to a healthcare provider, 
participant in accordance with this protocol. L ocal he alth authority  regulations or investigator 
site guidelines may  use alternative terms for these activities.
See the package insert ( carbamazepi[INVESTIGATOR_050] ) for instructions on how to prepare the study  
intervention for administration. Study  intervention should be prepared and dispensed by  [CONTACT_160440] y qualified and experienced member of the study  staff (eg, phy sician, nurse, 
physician’s assistant, nurse practitioner, pharmacy assistant/technician, or pharmacist) as 
allowed b y local, state, and institutional guidance. A second staff member will verify  the 
dispensing.
6.3.Measures to Minimize Bias: Randomization and Blinding
6.3.1. Allocation to Study I ntervention
The investigator’s knowledge of the treatment should not influence the decision to enroll a 
particula r participant or affect the order in which participant s are enrolled.
The investigator will assign participant numbers to the participant s as they  are screened for 
the study . All participants enrolled will receive treatment according to the dose/schedule.
6.4.
Study Intervention Compliance
When participants are dosed at the site, they  will receive study  intervention directly  from the 
investigator or designee, under medical supervision. The date and time of each dose 
administered in the clinic will be recorded in the source documents and recorded in the CRF.
The dose of stud y intervention and study participant identification will be confirmed at the 
time of dosing b y a member of the stud y site staff other than the person administering the 

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 40study  intervention. Study site personnel will examine each participant’s mouth to ensure that 
the study  intervention was ingested.
6.5. Dose Modification
No dose modification is anticipated .
6.6.Continued Access to Study Intervention A fter the End of the Study
No intervention will be provided to study  participants at the end of their study  participation.
6.7.Treatment of Overdose
For this study , any  dose of PF -07321332 greater than 600 mg or ritonavir greater than 
200mg or ca rbamazepi[INVESTIGATOR_769068] 600 mg within a 24 -hour time period (2hours) will 
be considered an overdose .
There is no specific treatment for an overdose of either PF -07321332 or ritonavir or 
carbamazepi[INVESTIGATOR_050] .
In the event of an overdose, the investigator should:
Contact [CONTACT_22840] 24 hours.
Closely  monitor t he participant for an y AEs/SAEs and laboratory  abnormalities for at 
least 5 half -lives or 28 calendar day s after the overdose of PF -07321332 or ritonavir 
(whichever is longer).
Document the quantit y of the excess dose as well as the duration of the overdose in 
the CRF.
Overdose is reportable to [COMPANY_007] Safety  only when associated with an SAE.
Obtain a blood sample for PK anal ysis within 1days from the date of the last dose of 
study intervention if requested by  [CONTACT_7195] (determined on a case -by-case 
basis).
6.8.Concomitant Therapy
Use of prescription or nonprescription drugs and dietary  and herbal supplements are 
prohibited within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study  
intervention. L imited use of nonprescription medications that are not believed to affect 
participant safety  or the overall results of the study may
 be permitted on a case -by-case basis 
following approval b y the spon sor.Acetaminophen/paracetamol may  be used at doses 
of ≤1 g/day .
Herbal supplements and hormonal methods of contraception (including oral and transdermal 
contraceptives, injectable progesterone, vaginal ring, and postcoital contraceptive methods)

PF-[ADDRESS_1055103].
Participants taking MAO inhibitors should discontinue MA Oinhibitor for a minimum of 
14days prior to dosing in the current study .
As carbamazepi[INVESTIGATOR_769069]3A4, the potential exists for interactions
between carba mazepi[INVESTIGATOR_769070]3A4. Agents that are inhibitors are 
expected to increase plasma levels of carbamazepin e: cimetidine, clarithromy cin, 
acetazolami de, gluosetime, grapefruit juice, itraconazole, nefazadone, protease inhibi tors, 
valproate, and verapamil. Thus if a partic ipant will have been titrated to a stable dose (ie, 
300mg BID) of carbamazepi[INVESTIGATOR_050], it is reasonable to expect that a d ose reduction for 
carbamazepi[INVESTIGATOR_769071] .
The potential also exists for patients taking inducers of CYP3A4 that would be expected to 
decrease plasma levals of carbamazepi[INVESTIGATOR_050]
: ciplastin, doxorubnincin HCL , Gelbamate, 
rifampin, phenobarbital, pheny toin, and theo phylline. Thus if a participant will ha vebeen 
titrated to a stable dose (ie, 300 mg BID) of carbamazepi[INVESTIGATOR_050], and then begins a course of 
treatment with one of these inducers, it is reasonable to expect that a dose increase for 
carbamazepi[INVESTIGATOR_769071] .
All concomitant treatments taken during the study  must be recorded with indication, daily  
dose, and start and stop dates of administration. All participants will be questioned about 
concomitant treatment at each clinic visit.
Treatments taken within [ADDRESS_1055104] dose of study  intervention 
will be documented as concomitant treatments.
6.8.1. Rescue Medicine 
There is no rescue therapy to r everse the AEs observed with PF-
07321332, ritonavir or 
carbamazepi[INVESTIGATOR_050] ; standard medical supportive care must be provided to manage the AEs. 
7.DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL
7.1.Discontinuation of Study Interventi on
It may  be necessary  for a participant to permanently  discontinue study  intervention .Reasons 
for permanent discontinuation of study  intervention include the following ;
AE requiring discontinuation in investigator’s view
,
Pregnancy ,
Positive COVI D-[ADDRESS_1055105] (ie,RT-PCR) .

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 42If study  intervention is permanentl y discontinued, the participant will not remain in 
the study  for further evaluation. See the SoA for data to be collected at the time of 
discontinuation of study  intervention.
7.1.1. ECG Changes
A participant who meet s either bulleted criterion based on the average of triplicate ECG 
readings will be withdrawn from the stud y intervention. 
QTcF >500 msec.
Change from baseline: QTcF >60 msec and QTcF >450 msec.
If a clinically  significant finding is identified (including, but not limited to ,changes from 
baseline in QTc Fafter enrollment ), the investigator or qualified designee will determine if 
the participant can continue in the study  and if any change in participant management is 
needed. This review of the ECG printed at the time of collection must be documented. Any  
new clinicall y relevant finding should be reported as an AE.
7.1.2. Potential Cases of Acute Kidney Injury
Abnormal values in SCr concurrent with presence or absence of increase in BUN that meet 
the criteria below, in the absence of other causes of kidney  injury , are considered potential 
cases of acute kidney  injury  and should be considered important medical events. 
An increase of ≥0.3 mg/dL (or ≥26.5 µmol/L ) in SCr level relative to the participant’s own 
baseline measurement should trigger another assessment of SCr as soon as practicall y 
feasible, preferabl y within 48 hours from awareness.
If the second assessment (after the first observations of ≥0.3 mg/dL [or ≥26.5 µmol/L ] in SCr
relative to the participant’s own baseline measurement) is ≥0.4 mg/dL (or ≥35.4 µmol/L ), the 
participant should be discontinued from the stud y and adequate, immediate, supportive 
measures taken to correct apparent acute kidney  injury .
Participants should return to the investigator site and be evaluated as soon as possible, 
preferabl y within 48 hours from awareness of the second assessment confirming abnormal 
SCr result. This evaluation should include labor atory  tests, detailed history , and phy sical 
assessment. In addition to repeating SCr, laboratory tests should include serum BUN, serum 
creatine kinase, and serum electrol ytes (including at a minimum potassium, sodium, 
phosphate/phosphorus, and calcium), in addition to urinary  dipstick, urine microscopic 
examination, and urinary indices. All cases confirmed on repeat testing as meeting the 
laboratory  criteria for acute kidney  injury , with no other cause(s) of laboratory  abnormalities 
identified, should be co nsidered potential cases of drug -induced kidney  injury  irrespective of 
availability  of all the results of the investigations performed to determine etiology  of the 
abnormal SCr. If ≥2healthy  participants are noted to have 2 consecutive SCr results of 
≥0.3 mg/dL (or ≥26.5 µmol/L), an assessment of whether the finding may be considered an 
adverse drug reaction should be undertaken.

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 437.2.Participant Discontinuation/ Withdrawal F rom the Study
A participant may  withdraw from the study  at an y time at his/her own requ est. Reasons for 
discontinuation from the study  include the following:
Refused further study  procedures
Lost to follow -up
Death
Study  terminated by  [CONTACT_3211]
Investigator decision
Pregnancy
At the time of discontinuing from the stud y, if possible, an earl y discontinuation visit should 
be conducted. See the SoA for assessments to be collected at the time of study  
discontinuation and follow-up- and for an y further evaluations that need to be completed. 
The early  discontinuation visit applies only  to participants who are enrolled/ randomized and 
then are prematurely  withdrawn from the study .Participants should be questioned regarding 
their reason for withdrawal.
If a participant withdraws from the study , he/she may  request destruction of an y remaining 
samples taken and not tested
,and t he investigator must document any  such requests in the 
site study  records and notify  the sponsor accordingly .
If the participant withdraws from the study  and also withdraws consent (see S ection 7.2.1) 
for disclosure of future information, no further evaluations should be performed and no 
additional data should be collected. The sponsor may  retain and continue to use an y data 
collected before such withdrawal of consent.
7.2.1. Withdrawal of Consent 
Participant s who request to discontinue receipt of study  intervention will remain in the study  
and must continue to be followed for protocol specified follow -
up procedures. The onl y 
exception to this is when a participant specificall y withdraws consent for any further contact 
[CONTACT_78258]. Participant s should notify  the investigator in writing of the decision to withdraw 
consent from future follow -
up, whenever possible. The withdrawal of consent should be 
explained in detail in the medical records b y the investigator, as to whether the withdrawal is 
only from further receipt of study  intervention or also from study  procedures and/or 
posttreatment study  follow -up, and entered on the appropriate CRF page. In the event that 
vital status (whether the participant is alive or dead) is being measured, publicly  available 

PF-[ADDRESS_1055106] be taken if a participant fails to return to the clinic for a required 
study  visit:
The site must attempt to contact [CONTACT_14315] . Counsel the participant on the importance of maintaining the 
assigned visit schedule and ascertain whether the participant wishes to and/or should 
continue in the study .
Before a parti cipant is deemed lost to follow -up, the investigator or designee must 
make every  effort to regain contact [CONTACT_6635] (where possible, 3 telephone 
calls and, if necessary , a certified letter to the participant’s last known mailing 
address or local equivalent methods). These contact [CONTACT_14316]’s medical rec ord.
Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study. 
8.STUDY ASSESSMENTS AND PROCEDURES
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing any  study specific procedures.
Study  procedures and their timing are summarized in the SoA. Protocol waivers or 
exemptions are not allowed.
Safety  issues should be discussed with the sponsor imme diately  upon occurrence or 
awareness to determine whether the participant should continue or discontinue study  
intervention.
Adherence to the stud
y design requirements, including those specified in the SoA, is essential 
and required for stud y conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm e ligibility  or record reasons for 
screening failure, as applicable.
Participants will be screened within 28 days prior to administration of the study  intervention 
to confirm that they  meet the study  population criteria for the study . If the time between 

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 45screening and dosing exceeds 28 days as a result of unexpected delay s (eg, delay ed drug 
shipment), then participants do not require rescreening if the laboratory  results obtained prior 
to first dose administration meet eligibility  criteria.
Every  effort shoul d be made to ensure that protocol -required tests and procedures are 
completed as described. However, it is anticipated that from time to time there may  be 
circumstances outside the control of the investigator that may  make it unfeasible to perform 
the test. I n these cases, the investigator must take all steps necessary  to ensure the safet y and 
well-being of the participant. When a protocol required test cannot be performed, the 
investigator will document the reason for the missed test and an y corrective and preventive 
actions that he or she has taken to ensure that required processes are adhered to as soon as 
possible. The study  team must be informed of these incidents in a timely  manner.
Ifan IV catheter is utilized for blood sample collections, ECGs a nd vital sign assessments 
(pulse rate andBP) should be collected prior to the insertion of the catheter .
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact [CONTACT_19987] .
The total blood sampling volume for individual participant s in this study  is approximatel y 
185mL.The actual collection times of blood sampling may  change. Additional blood 
samples may  be taken for safet y assessments at times specified by [CONTACT_4618], provided the total 
volume taken during the study does not exceed 550 mLduring an y period of 60 consecutive 
days.
To prepare for stud y participation, participant s will be instructed on the information in 
Protocol Section 5.3 LifestyleConsiderations andSection 6.8 Concomitant Therap y.
8.1.Efficacy Assessments
Not applicable.
8.2.Safety Assessments
Planned time points for all safety  assessments are provided in the SoA .Unscheduled clinical 
laboratory  measurements may  be obtained at any  time during the stud y to assess any 
perceived safety  issues.
8.2.1. Physical Exam inations
A complete PEwill include , at a minimum, head, ears, ey es, nose, mouth, skin, heart and 
lung examinations, ly mph nodes, and gastrointestinal, musculoskeletal, and neurological 
systems. 
A brief PEwill include, at a minimum, assessments of general appearance, the respi[INVESTIGATOR_768733] s ystems, and participant reported sy mptoms.

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 46PEsmay be conducted by  a phy sician, trained phy sician's assistant, or nurse practitioner as 
acceptable according to local regulation. 
Height and weight w ill also be measured and recorded as per the SoA. For measuring weight, 
a scale with appropriate range and resolution is used and must be placed on a stable, flat 
surface. Participant s must remove shoes, bulky  layers of clothing, and jackets so that only  
light clothing remains. They  must also remove the contents of their pockets and remain still 
during measurement of weight. 
PEfindings collected during the stud y will be considered source data and will not be requi red 
to be reported, unless otherwise noted. An y untoward PEfindings that are identified during 
the active collection period and meet the definition of an AE or SAE ( Appendix 3 ) must be 
reported according to the p rocesses in Section 8.3.1 to Section 8.3.3.
8.2.2. Vital Signs
Supi[INVESTIGATOR_78235] ’s arm supported at the level of the heart and
recorded to the nearest mm Hg after approximately [ADDRESS_1055107]. The same arm 
(preferabl y the dominant arm) will be used throughout the study
. Participant s should be 
instructed not to speak during measurements. 
The same properl y sized and calibrated BP cuff will be used to measure BP each time. The 
use of an automated device for measuring BP and pulse rate is acceptable; however, when 
done manuall y, pulse rate will be measured in the brachial/radial artery  for at least 
30seconds. When the timing of t hese measurements coincides with a blood collection, BP 
and pulse rate should be obtained prior to the nominal time of the blood collection.
Additional collection times, or changes to collection times
,of BPand pulse rate will be 
permitted, as necessary ,to ensure appropriate collection of safety  data.
[IP_ADDRESS]. Respi[INVESTIGATOR_769072]  5minutes of rest in a supi[INVESTIGATOR_422091] [ADDRESS_1055108] and before BPmeasurement.
[IP_ADDRESS]. Temperature
Temperature will be measured orall y (other body  locations, eg ,tympanic, are acceptable 
provided the same method is used and documented throughout the stud y). No eating, 
drinking, or smoking is allowed for 15 minutes prior to the measurement.
8.2.3. Electrocardiograms
12-lead ECGs (triplicate) utilizing limb leads (with a 1 0second rh ythm strip) should be 
collected at times specified in the SoA section of this protocol using an ECG machine that 
automatically  calculates the heart rate and measures PR, QT, and QTc intervals and QRS 

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 47complex. Alternative lead placement methodology using torso leads (eg, Mason- Likar) 
should not be used given the potential risk of discrepancies with ECGs acquired using 
standard limb lead placement. All scheduled ECGs should be performed after the participan t
has rested quietl y for approximately 10minutes in a supi[INVESTIGATOR_2547]. 
To ensure safet y of the participant s, a qualified individual at the investigator site will make 
comparisons to baseline measurements. Additional ECG monitoring will occur if a) a 
postdose QTc Finterval is increased by  ≥60msecfrom the baseline andis >450 msecfor 
participants with normal renal function and >470 msec for participants with impaired renal 
function
; or b) an absolute QT value is ≥[ADDRESS_1055109] hourl y until 
QTc values from 2 successive ECGs fall below the threshold value that triggered the repeat 
measurement.
If a) a postdose QTc Finterval remains ≥60msecfrom the baseline andis >450 msecfor 
participants with normal renal function and >470 msec for participants with impaired renal 
function; or b) an absolute QT value is ≥500 msecfor an y scheduled ECG for greater than 
4 hours (or sooner, at the discretion of the investigator); or c) QTcFintervals get 
progressivel y longer, the participant should undergo continuous ECG monitoring. A 
cardiologist should be consulted if QTcF intervals do not return to less than the criteri alisted 
above after 8 hours of monitoring (or sooner, at the discretion of the investigator).
In some cases, it ma y be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality. It is important that leads beplaced in the 
same positions each time in order to achieve precise ECG recordings. If a machine read QTc 
value is prolonged, as defined above, repeat measurements may  not be necessary  if a 
qualified medical provider’s interpretation determines that the QTcF values are in the 
acceptable range.
ECG values of potential clinical concern arelisted in Appendix 7.
8.2.4. Clinical Safety Laboratory Assessments
See Appendix 2for the list of clinical safet y laboratory  tests to be performed and the SoA for 
the timing and frequency. All protocol required laboratory  assessments, as defined in 
Appendix 2, must be conducted in accordance with the laboratory  manual and the SoA. 
Unscheduled clinical laboratory  measurements may  be obtained at any  time during the study  
to assess an y perceived safet y issues
.
The investigator must review the laboratory  report, document this review, and record any  
clinically  relevant changes occurring during the study in the AE section of the CRF.
Clinically  significant abnormal laboratory  findings are those which are not associ ated with 
the underl ying disease, unless judged by  [CONTACT_78259]'s condition.

PF-[ADDRESS_1055110] dose of stud y intervention should 
be repeated until the values return to normal or baseline or are no longer considered clinicall y 
significant b y the investigator or medical monitor.
If such values do not return to normal/baseline wi thin a period of time judged reasonable by  
[CONTACT_093], the etiology  should be identified and the sponsor notified.
See Appendix 6for suggested actions and follow -
up assessments in the event of potential 
drug-induced liver injury.
Urine drug (mandatory ) and alcohol breath test (at discretion of investigator) will be 
performed at Screening and on Day  -1. These tests may  be performed at any  other time at the 
discretion of the investigator.
8.2.5. COVID -
[ADDRESS_1055111] will be performed after 4 day s 
(ie,upon completion of 4 × 24 hours in house), or if they  develop COVID -[ADDRESS_1055112] 
25mIU/mL. Pregnancy  tests will be performed in WOCBP at the times listed in the SoA .
Following a negative pregnancy  test result at screening, appropriate contraception must be 
commenced and a second negative pregnancy  test result will be required at the baseline visit 
prior the participant ’sreceiving the study  intervention . Pregnancy  tests will also be done 
whenever 1 menstrual cycle is missed during the active treatment period (or when potential 
pregnancy  is otherwise suspected) and at the end of the study . Pregnancy  tests may  also be 
repeated if requested b y IRBs/ECs or if required by [CONTACT_427]. If a urine test cannot be 
confirmed as negative (eg, an ambiguous result), a serum pregnancy  test is required. In such 
cases, the participant must be excluded if the serum pregnancy  result is positive .
8.2.7. Suicidal Ideation and Behavior Risk Monitoring
The C-SSRS is an interview based rating scale to sy stematically  assess suicidal ideation and 
suicidal behavior. Versions are ava ilable for Screening/Baseline (Lifetime).
The C -SSRS should be collected at time specified in the SoA table by  [CONTACT_769088]. The C -SSRS can also be administered at an y time in the study at the d iscretion 
of the 
investigator based on any  reasonable concern.
At each suicidal assessment as per SoA, participants felt to have significan tsuicidal ideation 
with actual plan and intent or suicidal behavior, must be evaluated b y a clinician/mental 
health professional skilled in the evaluation of suicidality
 in the partici pants by  [CONTACT_769089]-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 49training or experience who will determine if it is sa fe for the participant to continue in the 
trial. Specific criteria that indicate a need for such an assessment are:
Suicial ideation associate with actual intent and/or plan in the past y ear
Previous history  of suicide behaviors in the past 10 y ears
In the investigator’s judgment a risk assessment or exclusion is warranted .
A written cop y of the risk assessment to be included in the subject’s clinical record.
Other possible suicidality adverse events or other clinical observations may , based on the 
judgment of the investigator, also trigger a risk assessment and require a narrative. When 
there is a positive response to any  question on the C -SSRS, the invest igator should determine 
whether an adverse event has occurred.
Any subject that responds y es to items [ADDRESS_1055113]- baseline 
visit should simply  be ex cluded from the stud y.
8.3.Adverse Events ,Serious Adverse Events , and Other Safety Reporting
The definitions of an AE and an SAE can be found in Appendix 3.
AEs may  arise from s ymptoms or other complaints reported to the investigator by  [CONTACT_2416] (or, when appropriate, b y a caregiver, surrogate, or the participant's legall y 
authorized representative), or they  may  arise from clinical findings of the 
investigator or 
other healthcare providers (clinical signs, test results, etc.).
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether the 
event meets the criteria for classification as an SAE or cau sed the participant to discontinue 
thestudy  intervention (see Section 7.1). 
During the active collection period as described in Section 8.3.1, e ach participant will be 
questioned about the occurrence of AEs in a nonleading manner.
In addition , the investigator may  be requested by  [CONTACT_19989] y to obtain specific follow -
up 
information in an expedited fashion.
8.3.1. Time Period and Frequency for C ollecting AE and SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from the time the participant provides informed consent, 
which is obtained before the participant ’s participation in the study  (ie, before undergoing 
any study related procedure and/or receiving study intervention ), through and including a 

PF-[ADDRESS_1055114] SAE Report Form.
Investigators are not obligated to activel y seek information on AEsor SAE safter the 
participant has concluded study  participation . However, if the investigator learns of an y SAE, 
including a death, at an y time after a participant has completed the study , and he/she 
considers the event to be reasonabl y related to the study  intervention , the investigator must 
promptly  report the SAE to [COMPANY_007] using the CT SAE Report Form.
[IP_ADDRESS].
Reporting SAEs to [COMPANY_007] Safety
All SAEs occurring in a participant during the active collection period as described in 
Section 8.3.[ADDRESS_1055115] SAE Report Form immediately  upon 
awareness and under no circumstance should this exceed 24 hours, as indicated in 
Appendix 3. The investigator will submit any  updated SAE data to the sponsor within 
24
hours of it being available.
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection period, 
which begins after obtaining informed consent as described in Section 8.3.[ADDRESS_1055116] to th e CRF 
requirements as described in Section 5.4.
8.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AE sand SAE sand the 
procedures for completing and transmitting SAE reports are provided in Appendix 3.

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 51Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences.
8.3.3. Follow -upof AEs and SAEs
After the initial AE or SAE report, the investigator is required to proactively  follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain adequate information un til resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow- up (as defined in Section 7.3).
In general, follow -
up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 
possible causality . Any information relevant to the event, such as co ncomitant medications 
and illnesses, must be provided. In the case of a participant death, a summary  of available 
autopsy  findings must be submitted as soon as possible to [COMPANY_007] Safety . 
Further information on follow -up procedures is given in Appendix 3.
8.3.4.
Regulatory Reporting Requirements for SAEs
Prompt notification by  [CONTACT_11012] a n SAE is essential so that legal 
obligations and ethical responsibilities toward the safet y of participants and the safet y of 
astudy  intervention under clinical investigation are met.
The sponsor has a legal responsibility  to notify  both the local regulato ry authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. The 
sponsor will comply  with country specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, IRBs/ECs, and investigators.
Investigator safety  reports must be prepared for S[LOCATION_003]R saccording to local regulatory  
requirements and sponsor policy  and forwarded to investigators as necessary .
An investigator who receives S[LOCATION_003]Rs or other specific safet y information (eg, summary  or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD(s) for the 
study and will notify  the IRB/EC, if appropriate according to local requirements.
8.3.5. Environmental Exposure, Exposure During Pregnancy or Breastfeeding, and 
Occupational Exposure
Environmental exposure occurs when a person not enrolled in the study  as a participant 
receives unplanned direct contact [CONTACT_216480]. Such exposure 
may or may  not lead to the occurrence of an AE or S AE. Persons at risk for environmental 
exposure include healthcare providers, famil y members, and others who may be exposed. 
Anenvironmental exposure may  include exposure during pregnancy , exposure during 
breastfeeding, and occupational exposure.

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 52Any such exposure to the study  intervention under study  are reportable to [COMPANY_007] Safet y 
within 24 hours of investigator awareness.
[IP_ADDRESS]. Exposure During Pregnancy
An EDP occurs if:
A female participant is found to be pregnant while receiving or after discontinuing 
study intervention .
A male participant who is receiving or has discontinued study  intervention exposes 
afemale partner prior to or around the time of conception .
A female is found to be pregnant while being exposed or having been exposed to 
study  interventio n due to environmental exposure. Below are examples of 
environmental EDP :
A female family  member or healthcare provider reports that she is pregnant after 
having been exposed to the study  intervention by  [CONTACT_78262] .
A male famil y member or healthcare provi derwho has been exposed to the study  
intervention by  [CONTACT_78263] .
The investigator must report EDP to [COMPANY_007] Safety within 24 hours of the investigator’s 
awareness, irrespective of w hether an 
SAE has occurred. The initial information submitted 
should include the anticipated date of delivery  (see below for information related to 
termination of pregnancy). 
If EDP occurs in a participant or a participant’s partner, the investigator must report 
this information to [COMPANY_007] Safety on the CT SAE Report Form and an EDP 
Supplemental Form, regardless of whether an SAE has occurred. Details of the 
pregnancy  will be collected after the start of study  intervention and until [ADDRESS_1055117] dose.
If EDP occurs in the setting of environmental exposure, the investigator must report 
information to [COMPANY_007] Safety  using the CT SAE Report Form and EDP Supplemental 
Form. Since the exposure information does not pertain to the participant enrolled in 
the study , the information is not recorded on a CRF; however, a copy  of the 
completed CT SAE Report Form is maintained in the investigator site file.
Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome. The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  [COMPANY_007] Safet y of the outcome as
afollow -up to the initial EDP S upplemental Form. I n the case of a live birth, the structural 
integrit y of the neonate can be assessed at the time of birth. In the event of a termination, the 
reason(s) for termination should be specified and, if clinically  possible, the structural 

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 53integrit y of the terminated fetus should be assessed by [CONTACT_4692] (unless 
preprocedure test findings are conclusive for a congenital anomal y and the findings are 
reported).
Abnormal pregnancy  outcomes are considered SAEs. If the outcome of the pregnancy  meets 
the criteria for an SAE (ie, ectopic pregnancy , spo ntaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomal y in a liveborn baby, a terminated fetus, 
anintrauterine fetal demise, or a neonatal death), the investigator should follow the 
procedures for reporting SAEs. Additional inf ormation about pregnancy  outcomes that are 
reported to [COMPANY_007] Safet y as SAEs follows: 
Spontaneous abortion includ ingmiscarriage and missed abortion.
Neonatal deaths that occur within [ADDRESS_1055118] 
to causality , as SA Es. In addition, infant deaths after 1
month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly  related to 
exposure to the study  intervention. 
Additional information regarding the EDP may  be requested by  [CONTACT_456]. Further 
follow -up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s). In the case of paternal exposure, the 
investigator will provide the participant with the Pregnant Part ner Release of Information 
Form to deliver to his partner. The investigator must document in the source documents that 
the participant was given the Pregnant Partner Release of Information Form to provide to his 
partner.
[IP_ADDRESS]. Exposure During Breastfeeding
An ex posure during breastfeeding occurs if: 
A female participant is found to be breastfeeding while receiving or after 
discontinuing study  intervention .
A female is found to be breastfeeding while being exposed or having been exposed to 
study  intervention (ie , environmental exposure). An example of environmental 
exposure during breastfeeding is a female family  member or healthcare provider who 
reports that she is breastfeeding after having been exposed to the study  intervention 
by [CONTACT_78262] .
The investigator must report exposure during breastfeeding to [COMPANY_007] Safety  within 24 hours 
of the investigator’s awareness, irrespective of whether an SAE has occurred. The 
information must be reported using the CT SAE Report Form. When exposure during 
breastfeeding occur s in the setting of environmental exposure, the exposure information does 
not pertain to the participant enrolled in the stud
y,so the information is not recorded on 
a CRF. However, a cop y of the completed CT SAE Report Form is maintained in the 
investigat or site file.

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 54An exposure during breastfeeding report is not created when a [COMPANY_007] drug specificall y 
approved for use in breastfeeding women (eg, vitamins) is administered in accord with 
authorized use. However, if the infant experiences an SAE associated with such a drug, the 
SAE is reported together with the exposure during breastfeeding.
[IP_ADDRESS]. Occupational Exposure
The investigator must report any  instance of occupational exposure to [COMPANY_007] Safet y within 
24
hours of the investigator’s awareness using the CT SA E Report Form regardless of 
whether there is an associated SAE. Since the information about the occupational exposure 
does not pertain to a participant enrolled in the study , the information is not recorded on 
aCRF; however, a cop y of the completed CT SAE Report Form 
must be maintained in the 
investigator site file .
8.3.6. Cardiovascular and Death Events
Not applicable.
8.3.7. Disease Related -Events and/or Disease Related -Outcomes Not Qualifying as AEs 
or SAEs
Not applicable.
8.3.8. Adverse Events of Special Interest
AESI sare examined as part of routine safet y data review procedures throughout the clinical 
trial and as part of signal detection processes.
All AESI s must be reported as an AE or SAE following the procedures described in 
Section 8.3.[ADDRESS_1055119] SAE Report Form.
[IP_ADDRESS]. Lack of Efficacy
This section is not applicable because efficacy  is not expected in the study  population.
8.3.9. Medical Device Deficiencies
Notapplicable.
8.3.10. Medication Errors
Medication errors may  result from the administration or consumption of the study  
intervention by [CONTACT_19995] , or at the wrong time, or at the wrong dosage strength.
Exposures to the study  intervention under stud y may occur in clinical trial settings, such as 
medication errors.

PF-[ADDRESS_1055120] SAE Report 
Form to [COMPANY_007] Safety Within 
24 Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)Only  if associated with an SAE
Medication errors include:
Medication errors involving participant exposure to the study  intervention .
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the study participant .
Such medication errors occurring to a stud
y participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified within 24 hours .
Wheth er or not the medication error is accompanied by  [CONTACT_1149], as determined by  [CONTACT_1275], the medication error is recorded on the medication error page of the CRF and, if 
applicable, an y associated AE(s), serious and nonserious, are recorded on theAE pag e of the 
CRF.
Medication errors should be reported to [COMPANY_007] Safety within [ADDRESS_1055121] SAE Report 
Form only when associated with an SAE.
8.4.Pharmacokinetics 
8.4.1. Plasma for Analysis of PF-07321332 and Ritonavir
Blood samples of approximately 4mL, to provide approximately 1.5 mL plasma, will be 
collected for measurement of plasma concentrations of PF -07321332 and ritonavir as 
specified in the SoA.Instructions for the collection and handling of biological samples wil l 
be provided in the laboratory  manual or by  [CONTACT_456]. The actual date and time (24 -hour 
clock time) of each sample will be recorded.
The actual times may  change, but the number of samples will remain the same. All efforts 
will be made to obtain the sam ples at the exact nominal time relative to dosing. Collection of 
samples up to and including 10 hours after dose administration that are obtained within 
10% of the nominal time relative to dosing (eg, within 6 minutes of a 60minute sample) will 
not be captured as a protocol deviation, as long as the exact time of the collection is noted on 
the source document and the CRF. Collection of samples more than 10 hours after dose
administration that are obtained ≤1hour away  from the nominal time relative to dosing will 
not be captured as a protocol deviation, as long as the exact time of the collection is noted on 
the source document and theCRF . 

PF-07321332
Protocol C4671014Amendment 1, 02 Jul 2021
PFIZER CONFIDENTIAL
Page 56Samples will be used to evaluate the PK of PF-07321332 and ritonavir. Samples collected for 
analyses of PF-07321332 and ritonavir concentration may also be used to evaluate safety or efficacy aspects related to concerns arising during or after the study, for metabolite identification and/or evaluation of the bioanalytical method,  
Genetic analyses will not be performed on these plasma samples unless consent for this was 
included in the informed consent. Participant confidentiality will be maintained.
Samples collected for measurement of plasma concentrations of PF-[ADDRESS_1055122] be processed and shipped as indicated in the instructions provided to 
the investigator site to maintain sample integrity. Any deviations from the PK sample handling procedure (eg, sample collection and processing steps, interim storage or shippi[INVESTIGATOR_19944]), including any actions taken, must be documented and reported to the sponsor. On a case-by-case- basis, the sponsor may make a determination as to whether sample integrity has been compromised.
8.4.2. Plasma Qualitative Metabolite Profiling
Metabolite profiling is not being evaluated in this study.
 
 
 
 
8.6. Biomarkers
Biomarkers are not evaluated in this study.
8.6.1. Specified Gene Expression (RNA) Research 
Specified gene expression (RNA) research is not included in this study.
8.6.2. Specified Protein Research 
Specified protein research is not included in this study.CCI
CCI
CCI
PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 578.6.3. Specified Metabolomic Research 
Specified metabolomic research is not included in this study .
8.7.Immunogenicity Assessments
Immunogenicit y assessments are not included in this study .
8.8.Health Economics
Health e conomics/ medical resource utilization and health e conomics parameters are not 
evaluated in this study .
9.STATISTICAL CONSIDERATIONS
Detailed method ology  for summary  and statistical anal yses of the data collected in this study  
is outlined here and further detailed in theSAP, which will be maintained by  [CONTACT_456]. 
The SAP may  modify  what is outlined in the protocol where appropriate; however, any  major 
modifications of the primary  endpoint definitions or their anal yses will also be ref lected in a 
protocol amendment.
9.1.Statistical Hypotheses
No statistical hy pothesis will be tested in this study.
9.2.Analysis Sets
For purposes of analy sis, the following 
analysis sets are defined:
Participant Analysis 
SetDescription
PK Concentration The PK concentration population is defined as all participants 
assigned to investigational product and treated who have at 
least [ADDRESS_1055123] they actually  
received .
9.3. Statistical Analyses
The SAP will be developed and finalized before any anal yses are pe rformed and will 
describe the analyses and procedures for accounting for missing, unused, and spurious data.

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 58This section is a summary of the planned statistical analy ses of the primary  and secondary  
endpoints.
9.3.1. Other Safety Analyses
All safet y anal yses will be performed on the s afety population.
AEs, ECGs, 
BP, pulse rate , and safety  laboratory  data will be reviewed and summarized on 
an ongoing basis during the study  to evaluate the safet y of participant s. An y clinical 
laboratory , ECG, BP, and pulse rate abnormalities of potential clinic al concern will be 
described. Safet y data will be presented in tabular and/or graphical format and summarized 
descriptivel y, where appropriate.
Medical history  and PEand neurological examination information , as applicable, collected 
during the course of t he study  will be considered source data and will not be required to be 
reported , unless otherwise noted. However, any  untoward findings identified on phy sical 
and/or neurological examination s conducted 
during the active collection period will be 
captured a s AEs, if those findings meet the definition of an AE.Data collected at screening 
that are used for inclusion/exclusion criteria, such as laboratory  data, ECGs ,and vital signs ,
will be considered source data, and will not be required to be reported , unless otherwise 
noted. Demographic data collected at screening will be reported .
9.3.2. Statistical Methods for PK Data
The plasma concentrations of PF-07321332 and ritonavir will be listed and descriptivel y 
summarized by  [CONTACT_273480] . Individual participant, as well as 
mean and median profiles of the plasma concentration time data will be plotted by  [CONTACT_769090] (for individual) and nominal (for mean and median) times 
respectivel y. Mean and median profiles w ill be presented on both linear and semi -log scales. 
Forcomparison of AUC infand C maxwith and without carbamazepi[INVESTIGATOR_050] , box and whisker plots 
of these parameters will be plotted by  [CONTACT_768752]. 
Natural 
logtransformed parameters (AUC inf,AUC last,and C max) of PF-[ADDRESS_1055124]. Estimates of the adjusted mean differences ( Test-Reference)
and corresponding 90% CIs will be obtained from the model. The adjusted mean differences 
and 90% CIs for the differences will be exponentiated to provide estimates of the ratio of 
adjusted geometric means (Test/Reference) and 90% CI  for the ratios. PF -07321332/ritonavir
administered alone will be the Reference treatment and PF-
07321332/ritonavir 
coadministered with carbamazepi[INVESTIGATOR_769073].
Additional specifications about the tables, listings, and figures will be outlined in the SAP .
9.3.3. Deriv ation of Pharmacokinetic Parameters Prior to Analysis
The plas ma PK parameters for PF-[ADDRESS_1055125]*PF-07321332 /ritonavir Area under the plasma 
concentration -time profile 
from time zero to the time 
of the last quantifiable 
concentration ( Clast)Linear/Log trapezoidal method.
AUC inf PF-07321332 /ritonavir Area under the plasma 
concentration -time profile 
from time [ADDRESS_1055126]+(Clast*/k el), Where C last* is 
the predicted plasma concentration 
at the last quantifiable time point 
estimated from the log -linear 
regression analysis .
Cmax PF-07321332 /ritonavir Maximum plasma 
concentrat ionObserved directly from data.
Tmax*PF-07321332 /ritonavir Time for C max Observed directly from data as time 
of first occurrence.
t½*PF-07321332 /ritonavir Term inal elimination 
half-lifeLog e(2)/k el, where k elis the terminal 
phase rate constant calculated by a 
linear regression of the log -linear 
conce ntration -time curve. Only 
those data points judged to describe 
the terminal log -linear decline w ill 
be used in the regression.
CL/F*PF-07321332 /ritonavir Apparent clearance Dose/ AUC inf
Vz/F*PF-07321332 /ritonavir Apparent volume of 
distributionDose/(AUC inf×kel).
*As data permit.
9.4.Interim Analyses
No formal interim anal ysis will be conducted for this study .As this is an open -label
study ,the sponsor may  conduct unblinded reviews of the data during the course of the study  
for the purpose of safet y assessment, facilitat ing PK/PD modeling, and/or supporting clinical 
development.
9.5.Sample Size Determination
A sample size of 12 participants will provide adequate precision to estimate the effects of 
carbamazepi[INVESTIGATOR_769043]
-07321332. The expected widths of the 90% CIs with 80% 
coverage probability  are shown in the following table for a range of possible effects. 
Param eter Estimated Effect 
(100*Test/Reference)90% CI CI Width
AUC inf 60%
70%
80%
90%53%, 68%
62%, 79%
71%, 90%
80%, 102 %15%
17%
20%
22%

PF-[ADDRESS_1055127] 
(100*Test/Reference)90% CI CI Width
100% 88%, 113 % 25%
Cmax 60%
70%
80%
90%
100%55%, 65%
65%, 76%
74%, 87%
83%, 97%
92%, 108 %9%
11%
13%
14%
16%
These estimates are based on the assumption that within -participant standard deviations are 
0.14 and 0.091 for lnAUC infand lnC max, respectively, as obtained from ongoing clinical stud y 
C4671001 in healthy  participants.
12 participants will be enrolled in the study .Participants who withdraw from t he study  may  
be replaced at the discretion of the investigator upon consultation with the sponsor.

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 6110. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines , including the 
Declaration of Helsinki and CI OMS International Ethical Guide lines ;
Applicable ICH GCP guidelines;
Applicable laws and regulations , including applicable privacy  laws .
The protocol, protocol amendments, I CD, SRSD(s) , and other relevant documents 
(eg,advertisements) must be 
reviewed and approved by  [CONTACT_456] ,submi tted to an I RB/EC 
by [CONTACT_093], and reviewed and approved by  [CONTACT_1201]/EC before the study  is initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary  to eliminate an immediate 
hazard to study  participants.
Protocols and an y substantial amendments to the protocol will require health authority  
approval prior to initiation except for changes necessary to eliminate an immediate hazard to 
study  participants.
The investigator will be responsible for the following:
Providing written summaries of the status of the study  to the IRB/EC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  [CONTACT_1201]/EC ;
Notifying the IRB/EC of SAEs or other significant safet y findings as required by 
[CONTACT_1744]/EC procedures;
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH GCP guidelines, the I RB/EC, European regulation 
536/20 14 for clinical studies (if applicable), European Medical Device Regulation 
2017/745 for clinical device research (if applicable), and all other applicable local 
regulations .
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the investigator is aware of an y new 
information that might influence the evaluation of the benefits and risks of the study  
intervention , [COMPANY_007] should be informed immediately .

PF-[ADDRESS_1055128], and 
of an y serious breaches of this protocol or of the ICH GCP guidelines that the investigator 
becomes aware of.
10.1.2. Informed Consent Process
The investigator or his/her representative will explain the nature of the study , including the 
risks and benefits, to the participant and answer all questions regarding the study .The 
participant should be given sufficient time and opportunity  to ask questions and to decide 
whether or not to participate in the trial.
Participants must be i nformed that their participation is voluntary . Participants will be 
required to sign a statement of informed consent that meets the requirements of 21 CFR 50, 
local regulations, ICH guidelines, privacy  and data protection requirements, where 
applicable, an d the IRB/EC or study  center.
The investigator must ensure that each study  participant is fully  informed about the nature 
and objectives of the study, the sharing of data related to the study ,and possible risks 
associated with participation, including the risks associated with the processing of the 
participant ’s personal data. 
The participant must be informed that his/her personal study related
-data will be used by  [CONTACT_20004]. The level of disclosure must als o be 
explained to the participant.
The participant must be informed that his/her medical records may  be examined by  [CONTACT_160439], by  
[CONTACT_6667]/EC members, and b y inspectors from regulatory  authorities.
The investigator further must ensure that each study  participant is fully  informed about his or 
her right to access and correct his or her personal data and to withdraw consent for the 
processing of his or her personal data.
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study  and the date on which the written consent was 
obtained. The authorized person obtaining the informed consent must also si gn the IC D.
Participants must be reconsented to the most current version of the IC D(s) during their 
participation in the study .
A cop y of the IC D(s) must be provided to the participan t.
Participants who are rescreened are required to sign a new IC D.

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 6310.1.3. Data Protection
All parties will comply  with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study  site in encr ypted electronic form and/or 
paper and will be password -protected or secured in a locked room to ensure that only  
authorized study  staff have access. The study  site will implement appropriate technical and 
organizational measures to ensure that the persona l data can be recovered in the event of 
disaster. In the event of a potential personal data breach, the study site will be responsible for 
determining whether a personal data breach has in fact occurred and, if so, providing breach 
notifications as require d by [CONTACT_2371].
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant specific -numerical code. Any  
participant records or data sets that are transferred to the sponsor will contain the numerical 
code; participant names will not be transferred. All other identifiable data transferred to the 
sponsor will be identified by  [CONTACT_20007], participant specific -code. The study  site will 
maintain a confidential list of partic ipant s who participated in the study, linking each 
participant ’s numerical code to his or her actual identity and medical record ID. In case of 
data transfer, the sponsor will protect the confidentiality  of participant s’ personal data 
consistent with the c linical study agreement and applicable privacy  laws.
10.1.4. Committees Structure
[IP_ADDRESS]. Data Monitoring Committee 
This study  will not use a DMC.
10.1.5. Dissemination of Clinical Study Data
[COMPANY_007] fulfills its commitment to publicly  disclose clinical study  results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the EudraCT, and/or 
www.pfizer.com, and other public registries in accordance with applicable local 
laws/regulations. In addition, [COMPANY_007] reports study  results outside of the requirements of local 
laws/regulations pursuant to its SOPs.
In all cases, stud y results are reported b y [COMPANY_007] in an objective, accurate, balanced, and 
complete manner and ar e reported regardless of the outcome of the study  or the country  in 
which the study  was conducted.
www.clinicaltrials.gov
[COMPANY_007] posts clinical trial results on www.clinicaltrials.gov for [COMPANY_007]- sponsored interventional 
studies (conducted in patients) that evaluate the safety  and/or efficacy  of a product, 
regardless of the geographical location in which the study  is conducted. These r esults are 
submitted for posting in accordance with the format and timelines set forth by  [CONTACT_20008].

PF-[ADDRESS_1055129] for [COMPANY_007] -sponsored interventional studies in 
accordance with the format and timelines set forth by  [CONTACT_20009].
www.pfizer.com
[COMPANY_007] posts public disclosure s ynopses (CSR synopses in which an y data that could be used 
to identify  individual participants have been removed) on www.pfizer.com for [COMPANY_007]
sponsored interventional studies at the same time the corresponding study  results are posted 
to www.clinicaltrials.gov .
Documents within marketing authorization packages/submissions
[COMPANY_007] complies with the European Union Policy  0070, the proactive publication of clinical 
data to the EMA website. Clinical data, under Phase 1 of this policy ,includes clinical 
overviews, clinical summaries, C SRs, and appendices containing the protocol and protocol 
amendments, sample CRF s, 
and statistical methods. Clinical data, under Phase 2 of this 
policy ,includes the publishing of individual participant data. Policy  0070 applies to new 
marketing authorization applications submitted via the ce ntraliz ed procedure since 
01January 2015 and applications for line extensions and for new indications submitted via 
the centralized procedure since 
01July 2015.
Data sharing
[COMPANY_007] provides researchers secure access to patient- level data or full CSRs for the purposes 
of “bona -fide scientific research” that contribute sto the scientific understanding of the 
disease, target, or compound class. [COMPANY_007] will make data from these trials available 
24months after study  completion. Participant level -data will be anon ymized in accordance 
with applicable privacy  laws and regulations. CSRs will have personall y identifiable 
information redacted.
Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analy ses.Research teams must include a biostatistician. Data will not 
be provided to applicants with significant conflicts of interest, including individuals 
requesting access for commercial/competitive or legal purposes.
10.1.6. Data Quality Assurance
All participant dat a relating to the stud y will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data). The investigator is 
responsible for verify ing that data entries are accurate and correct by  [CONTACT_78274].
Guidance on completion of CRFs will be provided in the CRF Completion Requirements 
document.

PF-[ADDRESS_1055130] ensure that the CRFs are securel y stored at the study site in encrypted 
electronic and/or paper form and are password -protected or secured in a locked room to 
prevent access b y unauthorized third parties.
QTL s are predefined parameters that are monitored during the study . Important deviations 
from the QTLs and any remedial actions taken will be summarized in the clinical study  
report.
The investigator must permit study related -monitoring, audits, I RB/EC review, and 
regulatory  agency  inspections and provide direct access to source data documents. This 
verification may  also occur after study  completion. I t is important that the investigator(s) and 
their relevant personnel are available during the monitoring visits and possible audits or 
inspections and that sufficient time is devoted to the process.
Monitoring details describing strategy , including definition of study  critical data items and 
processes (eg, risk based -initiatives in operations and quality ,such as r isk management and 
mitigation strategies and analytical riskbased - m onitoring), methods, responsibilities, and 
requirements, including handling of noncompliance issues and monitoring techniques 
(central, virtual , or on- site monitoring) , are provided in the data management plan and IQMP
maintained and utilized by  [CONTACT_36613] .
The sponsor or designee is responsible for the data management of this study ,including 
quality  checking of the data.
Records and documents, including signed IC Ds, pertaining to the conduct of this study  must 
be retained b y the investigator for 15years after study  completion unless local regulations or 
institutional policies require a longer retention period. No records may  be destroy ed during 
the retention period without the written approval of the sponsor. No records may  be 
transferred to another location or part y without writ ten notification to the sponsor. The 
investigator must ensure that the records continue to be stored securel y for aslong as they  are 
maintained.
When participant data are to be deleted, the investigator will ensure that all copi[INVESTIGATOR_769074] y and irrevocabl
y deleted from all systems.
The investigator(s) will notify  the sponsor or its agents immediately  of any  regulatory  
inspection notification in relation to the study . Furthermore, the investigator will cooperate 
with the 
sponsor or its agents to prepare the investigator site for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection. The 
investigator site and investigator will promptly  resolve any  discrepancies that a re identified 
between the stud y data and the participant's medical records. The investigator will promptly  
provide copi[INVESTIGATOR_19946]. Before response 
submission to the regulatory  authorities, the investigator will provide the sponsor or its 
agents with an opportunity to review and comment on responses to an y such findings.

PF-[ADDRESS_1055131] be available.
Definition of what constitutes source data and its origin can be found inthe Source 
Document Locator, which is maintained by  [CONTACT_181880]’s designee ([COMPANY_007] Clinical Research 
Unit).
Description of the use of the computerized sy stem is documented in the Source Document 
Locator, which is maintained by  [CONTACT_456]’s designee ([COMPANY_007] Clinical Research Unit) .
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
Study  monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by  [CONTACT_325753], complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study  is 
being conducted in accordance with the currently  approved protocol and any  other study  
agreements, I CH GCP guideli nes, and all applicable regulatory  requirements.
10.1.8. Study and Site Start and Closure
The study  start date is the date on which the clinical study  will be open for recruitment of 
participants.
The first act of recruitment is the date of the first participant’s first visit and will be the study  
start date.
The sponsor designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of the sponsor. Study  sites will be closed upon study  
completion. A stud y site is considered closed when all required documents and study 
supplies have been collected and a stud ysite-closure visit has been performed.
Reasons for the earl y closure of a stud y site b y the sponsor may include but are not limited 
to:
Failure of t he investigator to comply  with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor's procedures, or the ICH GCP 
guidelines ;
Inadequate recruitment of participants by  [CONTACT_093];

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 67Discontinuation of further study  inter vention development .
If the stud y is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the ECs/IRBs, the regulatory  authorities, and any  CRO(s) used in the study  of 
the reason for termination or suspension, as specif ied by  [CONTACT_20013]. The investigator shall promptly  inform the participant and should assure 
appropriate participant therap y and/or follow -up.
Study  termination is also provided for in the clinical study  agreement. If there is any conflict 
between the contract and this protocol, the contract will control as to termination rights.
10.1.9. Publication Policy
The results of this study  may  be published or presented at scientific meetings b y the 
investigator after publication of the overall study  results or 1year after the end of the stud y 
(or study  termination), whichever comes first. 
The investigator agrees to refer to the primary  publication in any  subsequent publications ,
such as secondary manuscripts, and submit s all manuscripts or abstracts to the sponsor 
30days before submission. This allows the sponsor to protect proprietary  information and to 
provide comments , and the investigator will, on request, remove an y previously undisclosed 
confidential information before disclosure, exc ept for an y stud y-or [COMPANY_007]
intervention -related information necessary  for the appropriate scientific presentation or 
understanding of the study  results.
For all publications relating to the stud y, the investigator will compl y with recognized ethical 
standards concerning publications and authorship, including those established by  [CONTACT_19483].
The sponsor will comply  with the requirements for publication of the over all study  results 
covering all i nvestigator sites .In accordance with standard editorial and ethical practice, the 
sponsor will support publication of multicenter studies only  in their entirety and not as 
individual site data. In this case, a coordinating investigator [INVESTIGATOR_769075].
Authorship of publications for the overall study  results will be determined by  [CONTACT_78275] I nternational Committee of Medical Journal Editors authorship 
requirements. 
If publication is addressed in the clinical study  agreement, t he publication policy  set out in 
this section will not apply.
10.1.10. Sponsor’s Qualified Medical Personnel
The contact [CONTACT_1133]'s appropriately
 qualified medical personnel for the 
study  is documented in the study  contact [CONTACT_769091].

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 68To facilitate access to appropriatel y qualified medical personnel for study -related medical 
questions or problems, participants are provided with an ECC at the time of informed 
consent. The ECC contains, at a minimum, (a) protocol and study  intervention identifiers, (b) 
participant’s stud y identification number, (c) site emergency phone number active 
24hours/day , 7days per week.
The ECC is intended to augment, not replace, t he established communication pathway s 
between the investigator, site staff, and study  team. The ECC is to be used by  [CONTACT_78277] y only , as a means of reaching the investigator 
or site staff related to the care of a participant. 

PF-07321332
Protocol C4671014Amendment 1, 02 Jul 2021
PFIZER CONFIDENTIAL
Page 6910.2. Appendix 2: Clinical Laboratory Tests
The following safety laboratory tests will be performed at times defined in the SoA section of 
this protocol. Additional laboratory results may be reported on these samples as a result of the method of analysis or the type of analyzer used by [CONTACT_20019], or as derived from calculated values. These additional tests would not require additional collection of blood. Unscheduled clinical laboratory measurements may be obtained at any time during the study to assess any perceived safety issues.
Table 2. Protocol-Required Safety Laboratory Assessments
Hematology Chemistry Urinalysis Other
Hemoglobin
HematocritRBC count
MCV
MCHMCHCPlatelet countWBC count
Total neutrophils 
(Abs)Eosinophils (Abs)Monocytes (Abs)Basophils (Abs)Lymphocytes (Abs)BUN/urea and creatinine
Glucose (fasting)Calcium
Sodium
PotassiumChlorideTotal CO
2(bicarbonate)
AST, ALT
Total bilirubin
Alkaline phosphataseUric acidAlbuminTotal proteinLocal Dipstick:
pH
Glucose (qual)
Protein (qual)
Blood (qual)KetonesNitritesLeukocyte esterase
Laboratory:
Microscopy and 
culturea•SARS-CoV-2 RT-PCR
•TSH
•Free T4
•Urine drug screeningb
•Pregnancy test ( β-hCG)c
•aPTT
•PT-INR
•Fibrinogen
At screening only
•FSHd
•HIV
•HBsAge
•HBcAbe
•HCVAb 
•HBsAbe
•HLA-B*1502 & HLA-A*
3101
a. Only if urine dipstick is positive for blood, protein, nitrites, or leukocyte esterase and culture only if 
bacteriuria.
b. At screening and Day -1; The minimum requirement for drug screening includes cocaine, THC, 
opi[INVESTIGATOR_858]/opi[INVESTIGATOR_2438], benzodiazepi[INVESTIGATOR_1651], and amphetamines (others are site and study specific).
c. Serum or urine β-hCG for female participants of childbearing potential.
d. For confirmation of postmenopausal status only.e. HBsAb will be performed as reflex testing for any participant who is HBsAg and HBcAb positive.
The investigator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study in the AE section of the CRF.
Any remaining serum/plasma from samples collected for clinical safety laboratory 
measurements at baseline and at all times after dose administration may be retained and stored for the duration of the study.
 
 CCI
PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 7010.3. Appendix 3: Adverse Events: Definit ions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is an y untoward medical occurrence in a patient or clinical study 
participant, temporally associated with the use of study intervention, whether or 
not considered related to the study  intervention.
Note: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) 
temporally associated with the use of study  intervent ion.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or 
urinaly sis) or other safety  assessments (eg, ECG, radiological scans, vital sign 
measurements), including those that worsen from baseline, considered clinically  
significant in the medical and scientific judgment of the investigator. Any 
abnormal laboratory  test results that meet any  of the conditions below must be 
recorded as an AE:
Is associated with accompany ing s ymptoms;
Requires additional diagnostic testing or medical/surgical intervention ;
Leads to a change in study  dosing (outside of any  protocol -specified dose 
adjustments) or discontinuation from the study , significant additional 
concomitant drug treatment, or other therap y.
Exacerbation of a chronic or intermittent preexisting condition, including either 
an increase in frequency  and/or intensity  of the condition.
New condition detected or diagnosed after stud y intervention administration ,
even though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug --drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication. Overdose per se will not be reported as 
an AE or SAE unless it is an intentional overdose taken with possible 
suicidal/self-- harming intent. Such overdoses should be reported regardless of 
sequelae.

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 71Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments that are associated with the underl ying disease, unless judged by  [CONTACT_11009]’s condition.
The disease/dis order being studied or expected progression, signs, or s ymptoms 
of the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads t o the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day--fluctuations of preexisting disease(s) or condition(s) 
present or detected at the star t of the study  that do not worsen.
10.3.2. Definition of an SAE
AnSAE is defined as any untoward medical occurrence that, at any dose, meets one 
or more of the criteria listed below:
a.Results in death
b.Is life -threatening-
The term “life-threatening ”in the definition of “serious” refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event that hypotheticall y might have caused death if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_22770], hospi[INVESTIGATOR_12994] (usually  
involving at least an overnight stay ) at the hospi[INVESTIGATOR_23917]/or treatment that would not have been appropriate in the phy sician’s 
office or outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. 
If a complication prolongs hospi[INVESTIGATOR_23919], the 
event is serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was 
necessary , the AE should be considered serious.
Hospi[INVESTIGATOR_5187] a preexisting condition that did not worsen 
from baseline is not considered an AE.

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 72d.Results in persistent or significant disability/incapacity
The term disability means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance , such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle), thatmay interfere with or 
prevent every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Is a suspected transmission via a [COMPANY_007] product of an infectious agent, 
pathogenic or non -pathogenic, is considered serious.
The event may  be suspected from clinical s ymptoms or laboratory  findings 
indicating an infection in a participant exposed to a Pf izer product. The terms 
“suspected transmission” and “transmission” are considered s ynon ymous. These 
cases are considered unexpected and handled as serious expedited cases b y 
pharmacovigilance personnel. Such cases are also considered for reporting as 
product defects, if appropriate.
g.Other situations:
Medical or scientific judgment should be exercised by [CONTACT_216484] ,such as 
significant medical events that may  jeopardize the particip ant or may  require 
medical or surgical intervention to prevent one of the other outcomes listed in the 
above definition. These events should usually  be considered serious.
Examples of such events include invasive or malignant cancers, intensive 
treatment i n an emergency room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059], or development of 
drug dependency  or drug abuse.
10.3.3. Recording/Reporting and Follow -upof AE sand/or SAE sDuring the Active 
Collection Period
AE and SAE Recording /Reporting
The table below summarizes the requirements for recording AEs on the CRF and for 
reporting SAEs on the CT SAE Report Form to [COMPANY_007] Safet ythroughout the active 
collection period . These requirements are delineated for 3 ty pes of events: (1) SAEs; (2) 
nonserious AEs; and (3) exposure to the study  intervention under stud y during 
pregnancy  or breastfeeding, and occupational exposure. 

PF-[ADDRESS_1055132] SAE 
Report Form to [COMPANY_007] 
Safety Within 24 Hours 
of Awareness
SAE All All
Nonserious AE All None
Exposure to the study  
intervention under stud y 
during pregnancy  or 
breastfeedingAll AEs/SAEs associated 
with exposure during 
pregnancy  or breastfeeding
Note: Instances of EDP or 
EDB not associated with an 
AE or SAE are not captured 
in the CRF.All instances of EDP are 
reported (whether or not 
there is an associated 
SAE)*
All instances of EDB are 
reported (whether or not 
there is an associated 
SAE).**
Environmental or 
occupational exposure 
to the product under 
study  to a non -
participant (not 
involving EDP or EDB).None. Exposure to a study  
non-participant is not 
collected on the CRF.The exposure (whether or 
not there is an associated 
AE or SAE) must be 
reported.***
* EDP (with or without an associated AE or SAE): any  pregnancy  information 
is reported to [COMPANY_007] Safety using CT SAE Report Form and EDP 
Supplemental Form; if the EDP is associated with an SAE, then the SAE is 
reported to [COMPANY_007] Safet y using the CT SAE Report F orm. 
** EDB is reported to [COMPANY_007] Safety using the CT SAE Report Form which 
would also include details of an y SAE that might be associated with the 
EDB. 
*** Environmental or Occupational exposure : AEs or SAEs associated with 
occupational exposure are re ported to [COMPANY_007] Safety  using the CT SAE 
Report Form.

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 74When an AE or SAE occurs, it is the responsibility  of the investigator to review 
all documentation (eg, hospi[INVESTIGATOR_1088], laboratory  reports, and diagnostic 
reports) related to the event.
The investigator will then record all relevant AE or SAE information in the CRF.
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_007] Safety  in lieu of completion of the CT SAE Report 
Form /AEor SAE CRF p age.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_007] Safety .In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copi[INVESTIGATOR_19953] .
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever pos sible, the diagnosis 
(not the individual signs/sy mptoms) will be documented as the AE or SAE.
Assessment of Intensity
The investigator will make an assessment of intensity  for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories: 
Mild: Asymptomatic or mild sy mptoms; clinical or diagnostic observations only ; 
intervention not indicated.
Moderate: Minimal, local or noninvasive int ervention indicated; limiting age -
appropriate instrumental ADL. Instrumental ADL refers to preparing meals, 
shoppi[INVESTIGATOR_3112], using the telephone, managing money , etc.
Severe: Severe or medically  significant but not immediately  life-threat ening; 
hospi[INVESTIGATOR_3111]; disabling, limiting 
self care ADL. Self care ADL refers to bathing, dressing and undressing, feeding 
self, using the toilet, taking medications, and not bedridden.
An event is defined as “serious” when it meets at least 1 of the predefined 
outcomes as described in the definition of an SAE, NOT when it is rated as 
severe.

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 75Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE or SAE. The investigator will use clinical 
judgment to determine the relationship.
A “reasonable possibility” of a relationship conveys that there are facts, 
evidence, and/or arguments to suggest a causal relationship, rather than a 
relationship cannot be ruled out.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  intervention 
administration, will be considered and investigated.
The investigator will also consult the IB and/or product information, for 
marketed products, in his/her assessment.
For each AE or SAE, the investigator must document in the medical notes that 
he/she has reviewed the AE or SAE and has provided an assessment of causality .
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor. However, it is 
very important that the investigator always make an assessment of causality 
for every event before the initial transmission of the SAE data to the 
sponsor .
The investigator may  change his/her opi[INVESTIGATOR_19954] -
up-information and send a nSAE follow - up-report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
If the investigator does not know whether or not the study  intervention caused the 
event, then the event will be handled as “related to study  intervent ion” for 
reporting purposes, as defined by  [CONTACT_456] . In addition, if the investigator 
determines that an SAE is associated with study  procedures, the investigator 
must record this causal relationship in the source documents and CRF, and report 
such an a ssessment in the dedicated section of the CT SAE Report Form and in 
accordance with the SAE reporting requirements.
Follow -upof AEs and SAEs
The investigator is obligated to perform or arrange for the conduct of 
supplemental measurements and/or evaluations, as medically  indicated or as 
requested b y the sponsor ,to elucidate the nature and/or causalit y of the AE or 
SAE as fully  as possible. This may  include additional laboratory  tests or 

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 76investigations, histopathological examinations, or consultation with other 
healthcare providers .
If a participant dies during participation in the study or during a recognized 
follow -up- period, the investigator will provide [COMPANY_007] Safety  with a cop y of an y 
postmortem findings
,including histopathology .
New or upda ted information will be recorded in the originally  submitted 
documents .
The investigator will submit any  updated SAE data to the sponsor within 
24
hours of receipt of the information.
10.3.4. Reporting of SAEs
SAE Reporting to [COMPANY_007] Safety via an Electronic Data Collection Tool
The primary  mechanism for reporting an SAE to [COMPANY_007] Safety will be the 
electronic data collection tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool ( see next section) to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem as soon as the data
become available.
After the stud y is completed at a given site, the electronic data collection tool 
will be taken off -line to prev ent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives 
updated data on a previously  reported SAE after the electronic data collection 
tool has been taken off -line, then the site can report this information on a paper 
SAE form (see next section) or to [COMPANY_007] Safet y by [CONTACT_756].

PF-[ADDRESS_1055133] SAE Report Form
Facsimile transmission of the CT SAE Report Form is the preferred method to 
transmit this information to [COMPANY_007] Safety .
In circumstances when the facsimile is not working , notification by  [CONTACT_20021] a cop y of the CT SAE Report Form sent by  [CONTACT_20022].
Initial not ification via telephone does not replace the need for the investigator to 
complete and sign the CT SAE Report Form pages within the designated 
reporting time frames.

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 7810.4. Appendix 4: Contraceptive and Barrier Guidance
10.4.1. Male Participant Reproductive Inclusion Criteria
Male participants are eligible to participate if they  agree to the following requirements during 
the intervention period and for at least 28daysafter the last dose of stud y intervention, which
corresponds to the time needed to eliminate reproductive safet y risk of the study  
intervention(s) :
Refrain from donating sperm.
PLUS either :
Be abstinent from heterosexual intercourse with a female of childbearing potential as 
their preferred and usual lifesty le (abstinent on a long term-and persistent basis) and 
agree to remain abstinent .
OR
Must agree to use contraception/barrier as detailed below:
Agree to use a male condom and should also be advised of the benefit for a 
female partner to use a highl y effective method of contraception as a condom may  
break or leak when having sexual intercourse with a woman of childbearing 
potential who is not currently  pregnant.
Inaddition to male condom use, a highl y effective method of contraception may be 
considered in WOCBP partne rs of male participants (refer to the list of highly  
effective methods below in Section 10.4.4).
10.4.2. Female Participant Reproductive Inclusion Criteria
A female participant is eligible to participate if she is not pregnant or breastfeeding, and at 
least 
1of the following conditions applies:
Is not a WOCBP (see definitions below inSection 10.4.3).
OR
Is a WOCBP and using a contraceptive method that is highly
 effective (with a failure 
rate of <1% per year), preferably with low user dependency , as described below
during the intervention period and for at least [ADDRESS_1055134] dose of study  
intervention ,which corresponds to the time needed to eliminate any  reproductive 
safet y risk of the study  intervention(s) .The investigator should evaluate the 
effectiveness of the contraceptive method in relationship to the first dose of study  
intervention.

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 79A WOCBP agrees not to donate eggs (ova, oocy tes) for the purpose of reproduction 
during this period. The investigator should evaluate the effectiveness of the 
contraceptive method in relationship to the first dose of study intervention.
The investigator is responsible for review of medical history , menstrual history , and recent 
sexual activity  to decrease the risk for inclusion of a woman with an earl y undetected 
pregnancy . 
10.4.3. Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopa usal 
unless permanentl y sterile (see below).
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before the 
first dose of study  intervention, additional evaluation should be 
considered.
Women in the following categories are notconsidered WOCBP:
1.Premenopausal female with 1 of the following:
Documented h ysterectomy ;
Documented bilateral salpi[INVESTIGATOR_1656] ;
Documented bilateral oophorectom y.
For individuals with permanent infertility  due to an alternate medical cause other than 
the above, (eg, mullerian agenesis, androgen insensitivity ), investigator discretion 
should be applied to determining study  entry .
Note: Documentation for any  of the above categories can come from the site 
personnel’s rev iew of the participant’s medical records, medical examination, or 
medical history  interview. The method of documentation should be recorded in the 
participant’s medical record for the stud y.
2.Postmenopausal female .
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. I n addition:
A high FSH level in the postmenopausal range must be used to confirm a 
postmenopausal state in women under 60 years old and not using hormonal 
contraception or HRT. 
A female on HRT an d whose menopausal status is in doubt will be required to 
use one of the non-estrogen hormonal highl y effective contraception methods 

PF-[ADDRESS_1055135].
10.4.4. Contracepti onMethods
Contraceptive use b y men or women should be consistent with local availability /regulations 
regarding the use of contraceptive methods for those participating in clinical trials.
Highly Effective Methods That Have Low User Dependen cy
1.Copper IU D
2.Bilateral tubal occlusion (eg, bilateral tubal ligation).
3.Vasectomized partner .
A vasectomized partner is a highl y effective contraceptive method provided that 
the partner is the sole sexual partner of the WOCBP and the absence of sperm has 
been confirmed. If not, an additional highl y effective method of contraception 
should be used. The s permatogenesis cy cle is approximately  90days.
Highly Effective Methods That Are User Dependent
4.Sexual abstinence .
Sexual abstinence is considered a highl y effective method only  if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study  intervention. The reliability  of sexual abstinence needs to be 
evaluated in relation to the duration of the stud y and the preferred and usual 
lifesty le of the participant.
One of the following effective barrier methods must be used in addition to the highl y 
effective methods listed above that are user dependent:
Male or female condom with or without spermicide;
Cervical cap, diaphragm, or sponge with spermicide;
A combination of male condom with either cervical cap, diaphragm, or sponge with 
spermicide (double -barrier methods) .

PF-07321332
Protocol C4671014Amendment 1, 02 Jul 2021
PFIZER CONFIDENTIAL
Page 81CCI
PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 8210.6. Appendix 6: Liver Safety: Suggested Actions and Follow-U p Assessments
Potential Cases of Drug Induced -Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  [CONTACT_20023]) are termed “tolerators,” while those who show transient liver injury  but adapt 
are termed “adaptors.” In some participant s, transaminase elevations are a harbinger of a 
more serious potential outcome. These participant s fail to adapt and therefore are 
"susceptible" to progressive and serious liver injury, commonl y referred to as DILI.
Participant s who experience a transamina se elevation above 3 ×ULN should be monitored 
more frequently  to determine if they  are “adaptor s” or are “susceptible.”
In the majority  of DILI cases, elevations in AST and/or ALT precede TBili elevations 
(>2×ULN) b y several day s or weeks. The increase in TBili ty pi[INVESTIGATOR_216474]/ALT 
is/are still elevated above 3 ×ULN (ie, AST/ALT and TBili values will be elevated within 
the same lab oratory sample). In rare instances, by [CONTACT_769092], 
AST/AL T values might have decreased. This occurrence is still regarded as a potential DILI.
Therefore, abnormal elevations in either AST OR AL T in addition to TBili that meet the 
criteria outlined below are considered potential DILI (assessed per Hy ’s law criteria) cases
and should alway s be considered important medical events, even before all other possible 
causes of liver injury  have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the 
participant ’s individual baseline values and underly ing conditions. Participant s who present 
with the following laboratory  abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively  determine the etiology  of the abnormal laboratory  values:
Participant s with AST/ALT and TBili baseline values within the normal range who 
subsequently  present with AST OR AL T values >3 ×ULN AND a TBili value 
>2×
ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available.
For participant s with baseline AST OR ALT ORTBili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 ×ULN; or >8 ×ULN (whichever is 
smaller).
Preexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at least 1 × ULN orif the value reaches 
>3×ULN (whichever is smaller).

PF-[ADDRESS_1055136]/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor. 
The participant should return to the investigator site and be evaluated as soon as possible, 
preferabl y within [ADDRESS_1055137] and AL T and TBili for suspected Hy ’s law 
cases , additional laboratory  tests should include albumin, CK, direct and indirect bilirubin, 
GGT, PT/INR, total bile acids, and a
lkaline phosphatase. Consideration should also be given 
to drawing a separate tube of clotted blood and an anticoagulated tube of blood for further 
testing, as needed, for further contemporaneous analy ses at the time of the recognized initial 
abnormalities to determine etiology . A detailed history , including relevant information, such 
as review of ethanol, acetaminophen /paracetamol (either by  [CONTACT_20025] a coformulated 
product in prescription or over -the-counter --medications) , recreational drug, or supplement 
(herbal) use and consumption, family  history , sexual history , travel history, history  of contact 
[CONTACT_4490] a jaundiced person, surgery , blood transfusion, history  of liver or allergic disease, and 
potential occupational exposure to chemicals, should be collected. Further testing for acute 
hepatitis A, B, C, D, and E infection ,liver imaging (eg, biliary  tract) ,and collection of serum 
sample s for acetaminophen/paracetamol drug and/or protein adduct levels may be warranted. 
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found. Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigati ons have been received and have excluded an alternative etiology .

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 8410.7. Appendix 7: ECG Findings of Potential Clinical Concern
ECG Findings T hat May Q ualify as AEs
Marked sinus bradycardia (rate <40 bpm) lasting minutes.
New PR interval prolongation >280 ms ec.
New prolongation of QTcF to >480 ms ec(absolute) or by≥60msecfrom 
baseline .
New onset- atrial flutter or f ibrillation, with controlled ventricular response rate:
ie, rate <120 bpm .
New onset- typeI second -degree -(Wenckebach) AV block of >30 seconds ’
duration
.
Frequent PVCs, triplets , orshort intervals (<30 seconds) of consecutive 
ventricular complexes .
ECG Findings T hat May Q ualify as SAEs
QTcF prolongation >500 ms ec.
New ST- T changes suggestive of my ocardial ischemia .
New onset- left bundle branch block (QRS >120 ms ec).
New onset - r ight bundle branch block (QRS >120 ms ec).
Symptomatic bradycardia .
Asystole:
In awake, s ymptom free- participant s in sinus rhy thm, with documented 
periods of as ystole ≥3.0 seconds or an y escape rate <40 bpm, or with an 
escape rh ythm that is below the AV node. 
In awake, s ymptom free- participant s with atrial fibrillation and brad ycardia 
with [ADDRESS_1055138] 5 seconds or longer. 
Atrial f lutter or fibrillation, with rapid ventricular response rate: rapid = rate 
>120 bpm.
Sustained s upraventricular tachycardia (rate >120 bpm) (“sustained ”= short 
duration with relevant symptoms or lasting >1 minute) .

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 85Ventricular r hythms >30 seconds’ duration, including idioventricular rhy thm 
(heart rate <40 bpm), accelerated idioventricular rhy thm ( HR > 40bpm to
<100 bpm), and monomorphic/poly morphic ventricular tach ycardia (HR 
>100 bpm (such as torsades de pointes) ).
Type IIsecond -degree -(Mobitz II)AVblock.
Complete (third
-degree -) heart block.
ECG Findings T hat Q ualify as SAEs
Change in pattern suggestive of new m yocardial infarction .
Sustained ventricular t achy arrhy thmias (>30 seconds ’duration) .
Second- or third -degree -AV block requiring pacemaker placement.
Asystolic pauses requiring pacemaker placement.
Atrial flutter or fibrillation with rapid ventricular response requiring 
cardioversion .
Ventricular fibrillation/ flutter .
At the discretion of the investigator, an y arrh ythmia classified as an adverse 
experience .
The enumerated list of major events of potential clinical concern are recommended as “alerts ”or 
notifications from the core ECG lab oratory to the investigator and [COMPANY_007] study team ,and not to be 
considered as all -inclusive of what to be reported as AEs/SA Es.

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 8610.8. Appendix 8: Prohibited and Precautionary Concomitant Medications That May 
Result in DDI
The prohibited concomitant medications listed below should not be taken with PF-[ADDRESS_1055139] of drugs prohibited or precautionary  for potential DDI concerns with the I MP may  
be revised during the course of the stud y with written not ification from sponsor, to include or 
exclude specific drugs or drug categories for various reasons ( eg,emerging DDI results for 
the IMP, availability  of new information in literature on the DDI potential of other drugs).
This is not an all -inclusive lis t. Site staff should consult with the sponsor or designee with 
any questions regarding potential DDI.
Prohibited Medications
Medications that are Strong Inducers of CYP3A4a
Drug Class Specific Medication Clinical Comments
Anti -infectives Rifampin Potential to impact the PK of PF-
[ADDRESS_1055140]. John's wort
Medications Dependent on CYP3A4 for Clearance, with Drug Interactions with
PF-07321332/ritonavira
Alpha 1 -Adrenoreceptor 
AntagonistAlfuzosin Risk of hypotension, syncope
Antianginal Ranolazine Risk of cardiac arrhythmias 
Antiarrhythmics Amiodarone, Bepridil, Flecainide, 
Propafenone, Quinidine, 
Dronedarone, EncainideRisk of cardiac arrhythmias 
Antihistamines Astemizole, Terfenadine Risk of cardiac arrhythmias
Ergot Derivatives Dihydroergotamine, Ergonovine, 
Ergotamine, MethylergonovineRisk of acute ergot toxicity 
(peripheral vasospasm and ischemia 
of the extremities)
HMG CoA Reductase 
Inhibitors Lovastatin, Simvastatin Risk of rhabdomyolysis; consider 
alternative agent : pravastatin
Neuroleptic Pi[INVESTIGATOR_768736] -5 inhibitors Sildenafil (Revatio) -PAH Risk of visual disturbances, 
hypotension, prolonged erection, and 
syncope
Sedatives/hypnotics Oral Midazolam, Triazolam Risk of prolonged sedation or 
respi[INVESTIGATOR_2341]
a.If a drug is not listed, it should not automatically be assumed it is safe to co -administer .

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 87Precautionary Medications
Medications to be Used with Caution when Co-administered with PF-07321332/ritonavi ra
Drug Class Specific Drugs Clinical Comments 
Anticonvulsants Lamotrigine, 
Valproate
Phenytoin
Carbamazepi[INVESTIGATOR_768737], valproate, and phenytoin 
concentrations. 
Coadm inistration may increase 
carbamazepi[INVESTIGATOR_53539] .Careful 
monitoring of adverse effects .
Alternative agents: Gabapentin 
Topi[INVESTIGATOR_768738]; consider 
alternative anticoagulant .
Antidepressant Trazadone, Desipramine, Fluoxetine 
Paroxetine, SertralineMay increase antidepressant 
concentration .
Anti -infective Erythromycin Coadm inistration may increase 
erythromycin concentration. 
Antifungals Itraconazole
VoriconazoleCoadm inistration may increase 
itraconazole concentration. Monitor for 
adverse effects.
Coadm inistration may decrease 
voriconazole concentration .
Calcium Channel 
Blockers Diltiazem, Verapamil, Felodipi[INVESTIGATOR_050], 
Nicardipi[INVESTIGATOR_050], Nisoldipi[INVESTIGATOR_050] , Amlodipi[INVESTIGATOR_768739]. The impact on the PR 
interval of co -administration of ritonavir 
with other drugs that prolong the PR 
interval (i ncluding calcium channel 
blockers) has not been evaluated. If 
coadministration is indicated, consider a 
dose reduction (amlodipi[INVESTIGATOR_768740] 50%). 
Close monitoring is recommended .
Cardiac Glycosides Digoxin Coadm inistration increases d igoxin 
concentration .
Contraceptives Hormonal contraception Recommend barrier method
Hepatitis C direct 
acting antiviralsBoceprevir, Glecaprevir/Pi[INVESTIGATOR_422098], 
Sofosbuvir/Velpatasvir/Voxilaprevir
Ombitasvir/Paritaprevir/ Ritonavir , 
DasabuvirCoadm inistration is not recommended as 
it resulted in increased plasma 
concentrations of Hep C antiviral; 
Caution or not recommended .
HIV Protease 
Inhibitors
NNRTs, Fusion 
InhibitorsLopi[INVESTIGATOR_054], Amprenavir, Indinavir, 
Nelfinavir, Saquinavir
Abacavir, Didanosine ,ZidovudineCoadm inistration may increase HIV 
protease inhibitor concentrations; 
coadminister with caution .
HMG CoA reductase 
inhibitorsAtorvastatin, Rosuvastatin Use with caution; risk of myopathy 
including rhabdomyolysis .Use low est 
dose of statin .
Alternative agents: Pravastatin .
Hypoglycemics Glipi[INVESTIGATOR_7130], Tolbutamide Potentially decrease glipi[INVESTIGATOR_422099]. 

PF-[ADDRESS_1055141] been observed
Fentanyl concentration may increase .
a.If a drug is not listed, it should not automatically be assumed it is safe to co -administer .

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 8910.9. Appendix 9: Abbreviations
The following is a list of abbreviations that may  be used in the protocol .
Abbreviation Term
 ongoing/continuous event
3CL 3C-like
3CLpro 3C-like protein
Ab Antibody
Abs Absolute
ADL activities of daily  living
AE adverse event
AED antiepi[INVESTIGATOR_769076] -time curve
AUC inf area under the plasma concentration -time curve from time [ADDRESS_1055142] measurable concentration
AV Atrioventricular
BBS Biospecimen Banking S ystem
BID twice a day
BMI body  mass index
BP blood pressure
bpm beats per minute
BUN blood urea nitrogen
C-SSRS Columbia -Suicide Severity  Ratiing Scale 
CFR Code of Federal Regulations
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CKD -EPI [INVESTIGATOR_19957] -Epi[INVESTIGATOR_769077]/F apparent clearance of drug from eg, plasma
Clast last observed ( quantifiable )plasma concentration
Cmax maximum observed plasma concentration
CO 2 carbon dioxide (bicarbonate)
COVID -[ADDRESS_1055143]-in-human
fm fraction metabolized
FSH follicle stimulating hormone
GCP Good Clinical Practice
GGT gamma-glutamyl transferase
GLP Good Laboratory Practice
HBcAb hepatitis B core antibody
HBsAb hepatitis B surface antibody
HBsAg hepatitis B surface antigen
HCL Hydrochloride
HCoV-229E human coronavirus 229E
HCoV-HKU1 human coronavirus HKU1
HCoV-NL63 human coronavirus NL63
HCoV-OC43 human coronavirus OC43
HCV hepatitis C virus
HCVAb hepatitis C antibody
HIV human immunodeficiency virus
HMG CoA 3-hydrox y-3-methyl-glutaryl-CoACCI
PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 91Abbreviation Term
hr(s) hour(s)
HR heart rate
HRT hormone replacement therap y
IB Investigator's Brochure
ICD informed consent document
ICH International Council for Harmonisation
ID Identification
IMP investigational medicinal product
IND Investigational New Drug 
INR international normalized ratio
IP investigational product
IPAL Investigational Product Accountability  Log
IQMP Independent Qualified Medical Practitioners
IRB Institutional Review Board
IV Intravenous
kel terminal phase rate constant calculated b y a linear regression of 
the log -linear concentration -time curve.
Ki inhibition constant
LBBB left bundle branch block
LFT liver function test
lnCmax log-transformed C max
Loge natural logarithm
MAD multiple ascending dose
MAO monoamine oxidase
MAOI monoamine oxidase inhibitors
MCH mean corpuscular hemoglobin
MCHC mean corpuscular hemoglobin concentration
MCV mean corpuscular volume
MERS Middle East respi[INVESTIGATOR_769078]
N/A not applicable
NHP non-human primate
NNRT non-nucleoside reverse transcriptase 
NOAEL noobserved adverse effect level
P1 Period 1
P2 Period 2
PAH pulmonary  arterial hy pertension
PCR polymerase chain reaction
PD pharmacod ynamic(s)
PDE -5 phosphodiesterase t ype 5

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 92Abbreviation Term
PE physical examination
pH potential of hy drogen
PK pharmacokinetic(s)
PO Orally
PR pulse rate
PT prothrombin time
PT-INR prothrombin time -international normalized ratio
PVC premature ventricular contraction/complex
q12h every  [ADDRESS_1055144]
QTc corrected QT interval
QTcF corrected QT (Fridericia method)
qual Qualitative
RBC red blood cell
RNA ribonucleic acid
RR respi[INVESTIGATOR_769079]-PCR reverse -transcriptase poly merase chain reaction
SAD single ascending dose
SAE serious adverse event
SAP Statistical Analy sis Plan
SARS -CoV -[ADDRESS_1055145] upper limit of normal
US [LOCATION_002]
USPI [INVESTIGATOR_185578] I nformation
Vz/F apparent volume of distribution

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 93Abbreviation Term
WBC white blood cell
WHO World Health Organization
WOCBP woman/women of childbearing potential

PF-07321332
Protocol C4671014
Amendment 1, 0 2Jul 2021
PFIZER CONFIDENTIAL
Page 9411.REFERENCES
1IIsu A, Granneman G, Bertz R. Ritonavir: Clinical pharmacokinetics and interactions 
with other anti -HIV agents. Clin Pharmacokinet. 1998;35 (4):275-91.
2World Health Organization. WHO Situation Report 51. 11 March 2020 . Geneva, 
Switzerland: World Health Organization; 2020. Available from: 
https://www.who.int/emergencies/diseases/novel- coronavirus- 2019/situation -reports. 
Accessed: 29 March 2020.
3Anand K, Ziebuhr J, Wadhwani P, et al. Coronavirus main proteinase (3CLpro) 
structure: basis for design of anti -SARS drugs. Scien ce.2003;300(5626) :[ADDRESS_1055146] of carbamazepi[INVESTIGATOR_769080] p3a4. Epi[INVESTIGATOR_8330]. 2007 
Mar;48(3):490- 6. doi: 10.1111/j.1528- 1167.2007.[ZIP_CODE].x. PMID: [ADDRESS_1055147] on hy droxy lation via 
CYP2C19. Br J Clin Pharmacol. 1997 Aug;44(2):186 -9. doi: 10.1046/j.1365-
2125.1997.[ZIP_CODE].x. PMID: 9278208; PMCID: PMC2042829.
6Dalton MJ, Powell JR, Messenheimer JA Jr, Clark J. Cimetidine and carbamazepi[INVESTIGATOR_050]: a 
complex drug interaction. Epi[INVESTIGATOR_8330]. [ADDRESS_1055148];27(5):553
-8. doi: 10.1111/j.1528 -
1157.1986.tb03583.x. PMI D: 3757941.,
7Stockis A, Chanteux H, Rosa M, Rolan P. Brivaracetam and carbamazepi[INVESTIGATOR_769081]. Epi[INVESTIGATOR_769082]. 2015 Jul;113:19- 27. doi: 
10.1016/j.eplepsyres.2015.03.003. Epub 2015 Mar 19. PMI D: 25986188.
